CDC Activities and Initiatives
Supporting the COVID-19 Response and the President’s Plan for Opening America Up Again

May 2020

Centers for Disease Control and Prevention (CDC)
Coronavirus Disease 2019 (COVID-19) Response
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC Activities and Initiatives Supporting the COVID-19 Response and the President’s Plan for Opening America Up Again</td>
<td>3</td>
</tr>
<tr>
<td>Appendix A: Surveillance for COVID-19</td>
<td>11</td>
</tr>
<tr>
<td>Appendix B: Healthcare System Surveillance</td>
<td>15</td>
</tr>
<tr>
<td>Appendix C: Guidance on Infection Control and Contact Tracing</td>
<td>18</td>
</tr>
<tr>
<td>Appendix D: Guidance on Test Usage (Asymptomatic Populations and Serology)</td>
<td>23</td>
</tr>
<tr>
<td>Appendix E: Assessing Surveillance and Hospital Gating Indicators</td>
<td>25</td>
</tr>
<tr>
<td>Appendix F: Setting Specific Guidance</td>
<td>40</td>
</tr>
</tbody>
</table>
This document briefly summarizes CDC’s initiatives, activities, and tools in support of the Whole-of-Government response to COVID-19.

**Overview of CDC’s Surveillance and Control Goals and Activities**

The principal objectives of COVID-19 surveillance are to monitor the spread and intensity of the pandemic, to enable contact tracing to slow transmission, and to identify disease clusters requiring special intervention. Secondary objectives include understanding the severity and spectrum of disease, identifying risk factors for and methods of preventing infection, and producing data essential for forecasting. In addition to tracking the disease itself, monitoring of healthcare capacity and essential supplies through the National Healthcare Safety Network (NHSN) is critical to ensure adequacy of care.

Because no single system can capture all parameters of the pandemic, CDC has implemented multiple, complementary surveillance systems ([Appendix A](#)). Key systems are case-based reporting through the National Notifiable Diseases Surveillance System (NNDSS), laboratory-based surveillance, syndromic-surveillance data reported through the National Syndromic Surveillance Program (NSSP), and data on healthcare system capacity reported through the NHSN ([Appendix B](#)). Additional systems, such as COVID-Net, provide rich, publicly available information for meeting secondary objectives. CDC continues to explore emerging and experimental surveillance platforms with a critical eye toward proven utility.

Control of the epidemic requires action at the individual, community, and population levels. CDC has provided state, tribal, local, and territorial health departments with extensive detailed guidance on [contact tracing](#), [infection control](#), and a wide range of other prevention and control topics. Recent models suggest that asymptomatic and pre-symptomatic transmission and delays in case recognition can greatly reduce the effectiveness of contact tracing. To enhance the speed and thus effectiveness of contact tracing, CDC is exploring technologic methods for instantaneous voluntary notification of contacts of confirmed cases.

At the community level, recent events have shown the devastating effects that outbreaks can have among vulnerable populations, especially those in congregate settings such as nursing homes, prisons, and homeless shelters. Similarly, outbreaks in food production plants and other critical industries are crippling communities financially and threatening national food security. Rapid identification and response to these events is a CDC priority that can mitigate the immediate impact and provide critical insights needed to prevent future outbreaks in similar settings. CDC has developed extensive tools to assist states, counties, facilities, and industries in responding to and preventing these events ([Appendix C](#)).

Laboratory testing of asymptomatic individuals is an evolving consideration as more is learned about the role of asymptomatic and subclinical infections in transmission SARS-COV-2. Emerging evidence suggests that asymptomatic infections may play an important role in the epidemiology of the disease. However, it is important to define the circumstances where testing asymptomatic persons is likely to be helpful in controlling the COVID-19 pandemic. Interim guidance about laboratory test usage for asymptomatic populations and for serologic testing and serologic surveillance is provided in [Appendix D](#).

Surveillance and hospitalization indicators can aid public health and government officials in their decisions when to reopen communities. The disease occurrence and hospital gating indicators in the *Opening Up America Again* guideline provide states and communities insight into the trajectory of the COVID-19 pandemic in their...
jurisdiction. These indicators are part of the broad assessment jurisdictions should undertake when deciding when and how to adjust community mitigation strategies for COVID-19 (Appendix E).

As businesses and other organizations gradually open after the COVID-19-related slowdown, they will need to consider a variety of measures for keeping people safe. These considerations include practices for scaling up operations, safety actions (e.g., cleaning and disinfection, social distancing), monitoring possible reemergence of illness, and maintaining health operations. Interim guidance for helping establishments with these steps is provided in Appendix F.

Widespread community mitigation combined with ongoing containment activities represents both an effective intervention for limiting the spread of COVID-19 and a serious threat to the economic well-being of the country and the world.
CRITICAL INITIATIVES AND ACTIVITIES

A. Expanding Testing and Advising Testing Practices

Extensive, rapid, and widely available COVID-19 testing is essential. CDC is working within the “All-of-Government and All-of-America Approach” to increase testing capacity and availability to improve case detection and contact tracing though all phases of the US plan to Opening Up America Again. As the supply and nature of tests expand, testing criteria have been broadened to include a wider range of people and situations.


Focusing Testing Efforts: CDC is working across the US government to support diverse efforts to increase testing in multiple settings to support diagnosis, surveillance, and outbreak control:

- **Testing for Diagnosis and Clinical Management:** CDC is working with federal government partners to support hospitals, healthcare systems, clinics, and public health departments to ensure the capability to diagnose COVID-19 infections with a turnaround time needed for appropriate clinical care and public health decision-making. CDC is:
  - Working with federal government partners to provide a wide range of technical assistance resources to each state to help them develop a state-specific testing plan that meets their unique needs.
  - Equipping state public health laboratories with sufficient quantities of devices, reagents, and testing supplies in the International Reagent Resource (IRR).
  - Working with the White House Coronavirus Task Force to enhance the national supply of reagents and testing supplies so that the commercial market is able to supply state efforts. This supply should be sufficient to achieve a rate of less than 10% positive tests for COVID-19 among symptomatic, asymptomatic, and pre-symptomatic individuals.

- **Testing for Surveillance and Outbreak Control:** Identify newly emergent cases or clusters of COVID-19 among symptomatic and asymptomatic individuals who are prioritized by public health officials and clinicians, and improve reporting of COVID-19 cases to public health systems. CDC is:
  - Utilizing established, nationwide surveillance systems to identify any areas of potential COVID-19 outbreaks, including use of CDC’s Influenza-Like Illness Network and the National Syndromic Surveillance Program.
  - Enabling public health systems at state, local, territorial, and tribal levels to develop a robust system to identify COVID-19 infections, particularly among vulnerable populations such as residents of nursing homes, people of racial and ethnic minority groups (e.g., African Americans, American Indians, Alaska Natives) at higher risk of disease, and those in areas of high social vulnerability, closed settings, and congregate housing.
  - Supporting existing case-based surveillance efforts for identifying infections through routine testing of persons in clinical encounters.
  - Enhancing case investigation and contact tracing efforts through increased public health staff and rapid testing capability.
  - Working with point-of-care diagnostic test manufacturers and state health departments to improve reporting of results from rapid, point-of-care devices.
  - Evaluating various serologic assays for use in surveillance and for potential use for returning to work.

Defining Usage: CDC is working with state, local, and other partners to define the circumstances where testing of asymptomatic persons is likely to be helpful in controlling the pandemic, as well as the best application of surveillance serologic testing.
• Emerging evidence suggests that asymptomatic infections play an important role in the epidemiology of SAR-CoV-2 infections. Testing for asymptomatic infection should focus (1) on persons with an increased likelihood of infection and (2) on settings with particularly vulnerable populations.

• CDC is working to identify indications for serologic testing. Broadly, the purpose of serologic test falls into two categories: serologic surveillance of populations and serologic testing of individuals to determine if they have had a prior infection. This current CDC COVID-19 test is not currently designed for individual use (i.e., to test people who want to know if they have been previously infected with SARS-CoV-2). Serologic surveillance has the potential to provide important insights into the transmission dynamics of disease, as well as a more complete picture of total burden of COVID-19 infections in a community or among first responders and front-line health providers. More information is needed to determine how the results of serologic testing correlate with possible immunity.

• See Appendix D and https://www.cdc.gov/coronavirus/2019-ncov/lab/serology-testing.html for additional details on testing strategies, testing of asymptomatic infections, and serologic testing.

**Augmenting Existing Infrastructure and Technology to Improve Data Flow and Reporting:**

CDC is supporting the improvement of current data infrastructure, and the development and integration of digital/technology solutions to augment state and community-wide sites to ensure timely and transparent communication to all citizens inclusive of daily new cases, hospitalizations, use of intensive care units (ICU), and mortality by county and or zip code. To ensure geographic relevant information is continuously available to state and local governments and the public in those communities, this should also include laboratory and potential immunization data systems. Activities include:

• Working with state and local officials and web development groups to develop and support interactive web-based platforms that allow open and transparent data visibility to all communities, such as the Florida Public Health COVID-19 website.

• Working with manufacturers for point-of-care diagnostic tests, commercial laboratories, state and local health departments, testing locations (providers, hospitals, pharmacies), and public health partners (Association of Public Health Laboratories [APHL], Council of State and Territorial Epidemiologists [CSTE]) to improve data quality, integration, and electronic reporting.

• Developing, integrating, and testing the ability for laboratories to securely share data with digital platforms selected by public health, including platforms that may be used for testing, or to support state and local contract tracing.

• Exploring digital solutions to share laboratory results with patients directly and sharing tested best practices with state and local partners. This could also extend to immunization record access.

• Developing recommendations for minimum requirements of platforms to integrate, store, and manage personal laboratory information on digital platforms (what states should consider before investing or having additional standards for platforms handling these data).

**B. Phased Plan and Indicators for Reopening America**

The plan for reopening America outlines a three-phased approach for reducing community mitigation measures while protecting vulnerable populations. The phased approach can be implemented statewide or community-by-community at governors’ discretion. The guidelines propose the use of six “gating” indicators to assess when to move through from one mitigation phase to another.
## Gating Criteria and Phase-specific Thresholds

<table>
<thead>
<tr>
<th>Gating Criteria</th>
<th>Threshold for entering Phase 1</th>
<th>Threshold for entering Phase 2</th>
<th>Threshold for entering Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreases in newly identified COVID-19 cases</td>
<td>Downward trajectory (or near-zero incidence) of documented cases over a 14-day period</td>
<td>Downward trajectory (or near-zero incidence) of documented cases for at least 14 days after entering Phase 1</td>
<td>Downward trajectory (or near-zero incidence) of documented cases for at least 14 days after entering Phase 2</td>
</tr>
<tr>
<td>Decreases in emergency department (ED) and/or outpatient visits for COVID-like illness (CLI)</td>
<td>Downward trajectory (or near-zero incidence) of CLI syndromic cases reported over a 14-day period</td>
<td>Downward trajectory (or near-zero incidence) of CLI syndromic cases reported for at least 14 days after entering Phase 1</td>
<td>Downward trajectory (or near-zero incidence) of CLI syndromic cases reported for at least an additional 14 days after entering Phase 2</td>
</tr>
<tr>
<td>Decreases in ED and/or outpatient visits for influenza-like illness (ILI)</td>
<td>Downward trajectory (or near-zero incidence) of ILI reported over a 14-day period</td>
<td>Downward trajectory (or near-zero incidence) of ILI reported for at least 14 days after entering Phase 1</td>
<td>Downward trajectory (or near-zero incidence) of ILI reported for at least an additional 14 days after entering Phase 2</td>
</tr>
<tr>
<td>Decreases in percentage of SARS-CoV-2 tests positive</td>
<td>Downward trajectory (or near-zero percent positive) of positive tests as a percentage of total tests over a 14-day period (flat or increasing volume of tests)</td>
<td>Downward trajectory (or near-zero percent positive) of positive tests as a percentage of total tests for 14 days after entering Phase 1 (flat or increasing volume of tests)</td>
<td>Downward trajectory (or near-zero percent positive) of positive tests as a percentage of total tests for at least 14 days after entering Phase 2 (flat or increasing volume of tests)</td>
</tr>
<tr>
<td>Treat all patients without crisis care</td>
<td>Jurisdiction inpatient &amp; ICU beds &lt;80% full Staff shortage in last week = no PPE supplies adequate for &gt;4 days</td>
<td>Jurisdiction inpatient &amp; ICU beds &lt;75% full Staff shortage in last week = no PPE supplies adequate for &gt;4 days</td>
<td>Jurisdiction inpatient &amp; ICU beds &lt;70% full Staff shortage in last week = no PPE supplies adequate for &gt;15 days</td>
</tr>
<tr>
<td>Robust testing program</td>
<td>Test availability such that percentage of positive tests is &lt;20% for 14 days Median time from test order to result is &lt;4 days</td>
<td>Test availability such that percentage of positive tests is &lt;15% for 14 days Median time from test order to result is &lt;3 days</td>
<td>Test availability such that the percentage of positive tests is &lt;10% for 14 days Median time from test order to result is &lt;2 days</td>
</tr>
</tbody>
</table>

Decisions to move between phases should also consider the public health capacity of the jurisdiction based on the criteria listed below. Other epidemiologic data sources available locally can be used to corroborate trends seen in core epidemiologic gating criteria. Special consideration should be given to infections identified in populations and settings such as healthcare personnel, patients in healthcare facilities (e.g., nursing homes, dialysis centers, long-term care facilities), and residents of congregate living settings (e.g., prisons, youth homes, shelters), underserved populations, and people of racial and ethnic minority groups (e.g., African Americans, American Indians, Alaska Natives) at higher risk of disease. Incidence and trajectory (increasing versus decreasing) of COVID-19 illnesses in the surrounding region should also be considered.
### Considerations for Assessing Capacity for Case Identification, Follow Up, and Containment

<table>
<thead>
<tr>
<th>Category</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 testing in jurisdiction</td>
<td>Testing is available as indicated for clinical, public health, and infection prevention needs.</td>
</tr>
<tr>
<td>Identification of new COVID-19 cases</td>
<td>All new COVID-19 cases in the jurisdiction can be rapidly identified through active surveillance, including proactive monitoring for asymptomatic cases through surveillance monitoring.</td>
</tr>
<tr>
<td>Interviewing new COVID-19 cases</td>
<td>Initial interviews can be conducted for nearly all new COVID-19 cases within one day of health department notification.</td>
</tr>
<tr>
<td>Contact tracing</td>
<td>Follow up (isolation, self-monitoring, and rapid testing of selected contacts) can be initiated for nearly all identified contacts of newly identified cases.</td>
</tr>
<tr>
<td>Incidence relative to local public health resources</td>
<td>Public health capacity is sufficient to fully perform contact tracing and investigate outbreaks based on local incidence and resources available.</td>
</tr>
</tbody>
</table>

While some communities will progress sequentially through the reopening phases, there is the possibility of recrudescence in some areas. Given the potential for a rebound in the number of cases or level of community transmission, a low threshold for reinstating more stringent mitigation standards will be essential. The decision to reinstate community mitigation strategies will undoubtedly be very difficult and will require careful thought to define an evidence-based monitoring strategy and specific guidance for these decisions.

### Technical Support for States

As part of the “Whole-of-Government” public health effort, CDC is providing states and other jurisdictions with technical assistance regarding testing, surveillance data collection and reporting, contact tracing, infection control, and outbreak investigation. Implementation of these activities is supported by the Paycheck Protection Program and Health Care Enhancement Act, which includes $11 billion to be awarded, within 30 days, directly to states, localities, territories, tribes, tribal organizations, urban Indian health organizations, or health service providers to tribes to develop, purchase, administer, process, and analyze COVID-19 tests, conduct surveillance, trace contacts, and related activities. Listed below are additional strategies CDC is using to strengthen the capacity of state, tribal, local, and territorial (STLT) health departments to fight against COVID-19. This technical assistance is essential to ready the nation to re-open and minimize future COVID-19 outbreaks in jurisdictions across the country.

### Contact Tracing

Contact tracing, a core disease control measure used by local and state health department personnel for decades, is a key strategy for preventing further spread of infectious diseases, including COVID-19. Contact tracing is part of the process of supporting affected individuals and warning contacts of exposure in order to stop chains of transmission. CDC is ramping up America’s capacity to perform contact tracing. As part of this effort, CDC has developed multiple training tools for communities to train the newest frontline workers in public health. CDC will train newly identified contact tracers on how to quickly locate and talk with the affected individuals, assist with isolation issues, and work with affected individuals to identify people with whom the affected individuals have been in close contact. Identification of contacts will allow further outreach by public health to identify individuals who need to self-isolate.
<table>
<thead>
<tr>
<th>Priorities</th>
<th>Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact tracing guidance and training</td>
<td>Provide <a href="https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/index.html">CDC guidance on case investigation and contact tracing to STLT health departments</a></td>
</tr>
<tr>
<td></td>
<td>• Address key issues such as staffing and roles, when to initiate an investigation, steps to the investigation, confidentiality and consent, self-isolation, quarantine, and necessary support services (housing, food, medicine); data management; digital contact tracing tools and technology; and evaluation and monitoring</td>
</tr>
<tr>
<td></td>
<td>• Work with states to develop a comprehensive proactive plan for the identification of asymptomatic case in areas of high vulnerability and/or high rates of co-morbidities</td>
</tr>
<tr>
<td>Deploy COVID-19 Response Corps</td>
<td>Use a multi-pronged approach to enhance and complement the efforts of STLT health department staff through innovative hiring mechanisms designed to address the surge staffing needs of STLT health departments.</td>
</tr>
<tr>
<td></td>
<td>Provide access to a variety of mechanism to complement local efforts to increase capacity.</td>
</tr>
<tr>
<td></td>
<td>• Realign existing CDC field staff</td>
</tr>
<tr>
<td></td>
<td>• Deploy CDC teams to address outbreaks in special settings</td>
</tr>
<tr>
<td></td>
<td>• Partner with CDC Foundation and other organizations to place surge staff for STLT health departments across the nation</td>
</tr>
<tr>
<td></td>
<td>• Partner with other federal agencies (e.g., AmeriCorps) to offer staffing options with states</td>
</tr>
<tr>
<td></td>
<td>• Facilitate access to a variety of contact tracing and case investigation training products and tools for a diverse and evolving public health workforce</td>
</tr>
<tr>
<td>Innovative technologies</td>
<td>Support implementation of innovative methods and technologies at the STLT levels to help inform and guide the national response.</td>
</tr>
<tr>
<td></td>
<td>• Develop guidance for assisting states and locals in evaluating tools, refining guidance, and identifying gaps in contact tracing workflow</td>
</tr>
<tr>
<td></td>
<td>• Leverage partnerships to facilitate information sharing among our state and local partners regarding digital contact tracing tools</td>
</tr>
<tr>
<td></td>
<td>• Share the landscape of digital tools, including those for <a href="https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/index.html">contact tracing</a>, case management, workforce management, and proximity tracking</td>
</tr>
</tbody>
</table>

**Conclusion**

As part of the Whole-of-Government Response, CDC has developed and is continually evaluating and improving the comprehensive surveillance program to generate essential data for tracking the pandemic and guiding the
overall response to COVID-19. In addition, CDC is working with federal, state, and local partners to improve testing and to advise and support communities during the phased reopening of America.
Appendix A: Surveillance for COVID-19

The goals of US surveillance are to produce timely and accurate information at national, state, local and community levels to inform decisions on public measures for implementing and adjusting disease reduction strategies, to guide clinical decisions, to educate the public and key stakeholders, and to provide data for estimating and forecasting disease burden.

Surveillance Objectives

- To identify both symptomatic and asymptomatic/presymptomatic cases and track contacts to slow transmission of COVID-19 in the United States
- To monitor spread and intensity of COVID-19 disease in the United States
- To understand disease severity and spectrum of illness
- To understand risk factors for severe disease and transmission
- To monitor for virus changes
- To estimate disease burden
- To produce data for forecasting spread and impact
- To identify when thresholds have been met to adjust community mitigation measures

Approach

Using multiple surveillance systems and epidemiology networks, CDC in collaboration with state, local, and academic partners, monitors the progression and impact of COVID-19 spread in the United States. The combination of data from the different systems is used to generate an ongoing picture of virus spread and produce data to address the key questions for directing and refining the US response. Surveillance data are used for:

- **Situational awareness** – Timely monitoring of the spread and intensity of COVID-19 disease in the United States. Surveillance systems allow for efficient targeting of public health measures, developing timely communications, and preparing health systems for increasing numbers of ill people. Data from these systems will be updated daily or weekly to create an ongoing, accurate understanding of impacted regions, affected populations, trends over time, and viral characteristics.

- **Understanding impact and forecasting disease spread** – All surveillance systems will be employed to produce data to understand overall impact and epidemic characteristics to inform future use of public health and medical resources.

- **Characterizing COVID-19 infection** across a spectrum of conditions include:
  - asymptomatic infections
  - symptomatic infection
  - medically attended outpatient and ambulatory visits
  - hospitalizations
  - deaths

Operational Plan

The plan is operationalized according to the following components:

- Increase laboratory testing and reporting to detect cases quickly and reliably for timely public health action
- Use robust syndromic surveillance, proactive monitoring for asymptomatic cases in settings with people at risk for infection or with known vulnerabilities
- Use laboratory reporting systems to monitor local disease trends to identify if thresholds (gates) have been met
- Corroborate trends and risk assessment with high-quality data from sentinel surveillance and systems
- Monitor disease and outbreaks in healthcare, institutional, workplace and group settings
- Use data for estimation of disease burden over time and to aid disease and transmission forecasts

**Federal, State, and Local roles**
The surveillance strategies rely on collaboration at federal, state, and local levels. The federal government will work with the states to establish the data platforms used by states and local jurisdictions to monitor transmission, public health, and health system capacity and provide technical assistance and coordination of information sharing and decision making across jurisdictions. These data platforms will be public facing to maximize transparency and maximize information to communities at the most granular level. Using the federal data systems, states can share data and information and communicate with residents’ decisions under consideration and clear guidance on adhering to mitigation levels. In addition to implementing federal programs, states can also coordinate resource allocation within their regions and across communities and monitor indicators closely to make decisive adjustments to mitigation measures. Finally, local governments are responsible for feeding data and information into state and federal data systems and adjoining communities.

**Components of the US COVID-19 surveillance plan**
The surveillance program is built on a combination of existing influenza and viral respiratory diseases surveillance systems, syndromic surveillance systems, case reporting systems, proactive monitoring for asymptomatic cases in areas of demonstrated vulnerabilities, commercial laboratory reporting, ongoing research platforms employed for the COVID-19 response, and new systems. The systems are summarized in Table 1 and a more fully described in Appendix A.

**Table 1. Surveillance Systems Used by Objective.** Surveillance data for decision-making uses multiple systems and epidemiology networks. These approaches use laboratory submitted specimens, electronically transmitted data, and other sources to generate an ongoing picture of disease spread, intensity, and severity, and produce data to address the key questions for directing and refining the US response.

<table>
<thead>
<tr>
<th>Goal addressed</th>
<th>Outcome</th>
<th>Platform</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trends in disease spread and intensity</td>
<td>No. of cases, by location, trends, demographics, underlying diseases, outcomes</td>
<td>COVID-19 case-based surveillance</td>
</tr>
<tr>
<td></td>
<td>No. of lab-positives; %positive, by age groups, location, over time</td>
<td>Public Health Laboratories (PHLs)</td>
</tr>
<tr>
<td></td>
<td>National Respiratory and Enteric Virus Surveillance System (NREVSS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Commercial labs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Outpatient, syndromic - %ILI, trends in ILI by region, age group, concordance and discordance between surveillance data</td>
<td>ILInet</td>
</tr>
<tr>
<td></td>
<td>National Syndromic Surveillance Program (NSSP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Outpatient – laboratory-confirmed, % positive, by location, by age group</td>
<td>Laboratory-confirmed outpatient (OP) surveillance</td>
</tr>
<tr>
<td></td>
<td>US Flu Vaccine Effectiveness (VE) network (acute respiratory illness)</td>
<td></td>
</tr>
<tr>
<td>Severity / clinical spectrum</td>
<td>Hospitalizations rates, by age group, underlying condition</td>
<td>FluSurvnet – all ages</td>
</tr>
<tr>
<td>Goal addressed</td>
<td>Outcome</td>
<td>Platform</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hospitalizations</td>
<td></td>
<td>New Vaccine Surveillance Network (NVSN) – pediatrics</td>
</tr>
<tr>
<td>Viral changes</td>
<td>Virus characterization, sequence changes</td>
<td>PHLS and CDC/DVD SPHERES</td>
</tr>
<tr>
<td>Risk factors for severe disease</td>
<td>Risk of severe disease given underlying illness, age</td>
<td>COVID-19 case-based surveillance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US Flu VE network</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FluSurvnet – all ages</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NVSN – pediatrics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Influenza ICU Vaccine Effectiveness Study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pediatric Intensive Care Influenza Network (PICFLU)</td>
</tr>
<tr>
<td>Disease burden</td>
<td>Overall number of persons affected by severity and age</td>
<td>All systems, plus additional special research studies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serologic surveys</td>
</tr>
<tr>
<td>Pandemic severity</td>
<td>Pandemic Influenza Severity Assessment (PISA)</td>
<td>Modeling based on epidemiological inputs</td>
</tr>
<tr>
<td>Forecasting and modeling spread and impact</td>
<td>When will it peak, how many disease outcomes, how will it spread</td>
<td>Modelling work with broad coalition of modelers led by CDC, using data above</td>
</tr>
<tr>
<td>Transmissibility</td>
<td>Attack rates and risk factors for transmission</td>
<td>Field studies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flu Transmission Evaluation Study (FluTEN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Household Influenza Vaccine Effectiveness Study (HIVES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pandemic cohorts (community, households, healthcare workers, pregnant woman, long-term care facilities)</td>
</tr>
<tr>
<td>Risk Factors for Severe disease</td>
<td>Risk of severe disease given underlying illness, age</td>
<td>COVID-19 Case-based surveillance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US Flu VE network</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FluSurvnet – all ages</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NVSN – pediatrics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HAIVEN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Influenza ICU Vaccine Effectiveness Study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PICFLU</td>
</tr>
<tr>
<td>Disease Burden</td>
<td>Overall number of persons affected by severity and age</td>
<td>All systems, plus additional special research studies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serologic surveys</td>
</tr>
<tr>
<td>Pandemic Severity</td>
<td>PISA</td>
<td>Modeling based on Epi inputs</td>
</tr>
<tr>
<td>Forecasting and modeling spread and impact</td>
<td>When will it peak, how many disease outcomes, how will it spread</td>
<td>Modelling work with broad coalition of modelers led by CDC, using data above</td>
</tr>
<tr>
<td>Goal addressed</td>
<td>Outcome</td>
<td>Platform</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Transmissibility</strong></td>
<td>Attack rates and risk factors for transmission</td>
<td>Field studies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FLuTES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HIVE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pandemic cohorts (community, households, HCWs, pregnant woman, LTCFs)</td>
</tr>
</tbody>
</table>
Appendix B: Healthcare System Surveillance

Rationale and Objective

Measuring and reporting the impact of COVID-19 on the capacity of the US healthcare system—including both acute-care hospitals and long-term care facilities—is an essential public health function in the pandemic response and in plans for Opening Up America Again. To make critical decisions, all levels of government, including federal, regional, state, local, tribal, and territorial, and the healthcare system need detailed and timely information about the availability and shortages of key resources, including hospital beds, intensive care unit (ICU) beds, ventilators, personal protective equipment, and healthcare personnel shortages. Reporting needs to be comprehensive across all states.

Regional variations in disease burden place a premium on supporting a surveillance system that can provide standardized data that are timely, easy to interpret, and readily accessible for multiple end users at all geographic levels. Among the main objectives for a national healthcare surveillance system in the current crisis are providing timely and readily available metrics with which to monitor the pandemic’s trajectory and progress toward Opening Up America Again. The key surveillance metrics available from NHSN are reported counts and a panel of additional summary statistics on hospitalized COVID-19 patients, hospital bed capacity, intensive care unit bed capacity, ventilatory capacity, supplies of personal protective equipment, and staffing shortages. These metrics, produced daily, serve as indicators that can drive decisions and actions at the national, state, county, tribal, territorial, and healthcare facility levels but needs to be expanded to be inclusive of all hospitals.

Key System

Implementation of several key surveillance metrics for monitoring the impact of the pandemic on the healthcare system are available through the existing Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN). NHSN’s role as a shared platform for healthcare-associated condition surveillance provides a powerful and unique foundation for COVID-19 surveillance.

CDC is already efficiently leveraging NHSN—which was launched in 2005 and now is the nation’s most widely used healthcare-associated condition tracking system—to support the nation’s COVID-19 response. NHSN provides a well-established technical infrastructure, readily extensible platform, and a strong set of partnerships with healthcare facilities, state and local health departments, the Centers for Medicare and Medicaid Services (CMS), and electronic health record system (EHRs) companies, and other healthcare information technology suppliers. This system will need to continue improving to ensure 100% reporting of all cases and outcomes.

The US healthcare system relies on NHSN to track healthcare-associated conditions, improve patient safety, fulfill mandatory federal and state reporting requirements, and ultimately eliminate healthcare-associated conditions. NHSN serves as the operating system for hospital-associated infection reporting through legislation established by 36 states, Washington, D.C., and Philadelphia, PA. NHSN will need to be expanded to all states and all hospitals to provide a comprehensive analysis of COVID-19. CMS uses NHSN reporting to enable healthcare facilities to fulfill CMS requirements for submitting healthcare outcome data that are used in CMS’s public reporting and incentive payment programs. Currently, over 25,000 healthcare facilities, including almost every hospital in the nation, more than 7,500 dialysis facilities, and over 3,000 nursing homes participate in NHSN. To be effective,
this system must be nationwide and be comprehensive in reporting. Personnel in these facilities have extensive experience submitting data to NHSN, adhering to the system’s surveillance protocols, and using their own data and national benchmarks provided by NHSN for local prevention and control purposes. NHSN’s collaborations with EHR companies, infection surveillance system providers, and the Health Level Seven (HL7) data standards organizations enable healthcare facilities to submit data electronically to NHSN by using HL7 data exchange specifications.

On March 27, 2020, CDC launched the NHSN COVID-19 Patient Impact and Hospital Capacity Module (https://www.cdc.gov/nhsn/covid19/report-patient-impact.html), and as of April 24, 2020, over 56% of acute care hospitals and over 53% of critical access hospitals have reported COVID-19 surveillance metrics. This level of participation needs to continue to improve until reporting is at the 95-100% range. Additionally, as of April 28, 2020, all ~15,000 nursing homes will be required to report COVID-19 cases and deaths, as well as staffing and personal protective equipment supply metrics, to NHSN (https://www.cdc.gov/nhsn/ltc/covid19/index.html) per a new CMS Interim Final Rule. The adaptation of NHSN to the immediate needs of the emergency response is a clear example of how CDC is retooling, modernizing, and updating its existing national surveillance capabilities to confront the pandemic.

During the COVID-19 pandemic, data on key metrics are submitted daily to NHSN, where the data are analyzed daily and presented out to the key components at all levels of the public health response. NHSN COVID-19 data are an integrally important asset in the US government response. The NHSN data are provisioned for use in secure access systems maintained by the White House Coronavirus Task Force, the National Response Coordination Center (NRCC), CDC, FEMA, ASPR, and CMS. In addition, all state health departments, several local health departments, and many HHS ASPR and FEMA Regional Offices receive data from NHSN and rely upon it for regional and state emergency response decisions.

NHSN uses COVID-19 data to develop and report national and state-wide estimates that serve as indicators of stress on the healthcare system. Figures below show examples of national trend-data as well as an example of a state trend.
NHSN Daily Crude Percent Occupancy, Louisiana

[Graph showing daily crude percent occupancy in Louisiana, with dates from 2020-04-01 to 2020-09-15. The graph includes lines for different categories such as percent of facilities reporting, percent of beds occupied, percent of inpatients with coronaviruses, percent of ICU beds occupied, and percent of ventilators used.]
Appendix C: Guidance on Infection Control and Contact Tracing


Infection Prevention Control

- What CDC is doing for infection control
- Standard CDC guidance on infection control in healthcare settings
- Best practices currently in use by states and private sector
- Link to virtual training
  - Preparing Nursing Homes and Assisted Living Facilities for COVID-19 (CDC webinar): https://www.youtube.com/watch?v=p1FiVFx5Q78
- Focus areas/congregate settings:
  - Long-term care facilities
  - Assisted living facilities
  - Dialysis facilities
  - Dental facilities
  - Ambulatory care facilities
  - Pharmacies
  - Emergency Medical Services (EMS)
  - Food processing facilities
    - Meat and Poultry Processing Workers and Employers: Interim Guidance from CDC and the Occupational Safety and Health Administration (OSHA)
  - Correctional facilities
    - Resources for Correctional and Detention Facilities:
  - Businesses

- Other IPC tools/Resources:


- External partners tools/resources
  - Society for Healthcare Epidemiology of America
    - Hospital epidemiology training - https://learningce.shea-online.org/content/sheacdc-outbreak-response-training-program-ortp#group-tabs-node-course-default1/index.php
    - Rapid Response Program podcast and webinar series https://learningce.shea-online.org/content/novel-coronavirus-covid-19
  - Association for Professionals in Infection Control and Epidemiology
    - COVID-19 Page: https://apic.org/covid19/
    - LTC text chapters: https://apic.org/resources/apic-text/apic-text-chapter-collection-long-term-care/

• Argentum (senior living) - Toolkit - https://www.argentum.org/coronavirustoolkit/

• Critical infrastructure workers

• Transportation and Delivery Workers:

• Airport, Airline Workers

• Other transit workers:

• Occupational Safety and Health Administration resources
  - Control and Prevention: https://www.osha.gov/SLTC/covid-19/controlprevention.html

• Return to work
• PPE reuse guidance
  o Strategies to Optimize the Supply of PPE and Equipment (including eye protection, isolation gowns, facemasks, N95 respirators, elastomeric respirators, and ventilators):
  o Decontamination and Reuse of Filtering Facepiece Respirators:
  o Personal Protective Equipment (PPE) Burn Rate Calculator:

• Sustainable Isolation
  o Links to federal programs- unemployment etc.
  o [www.coronavirus.gov](http://www.coronavirus.gov)
  o [https://www.coronavirus.gov/smallbusiness/](https://www.coronavirus.gov/smallbusiness/)
  o [https://www.usa.gov/unemployment](https://www.usa.gov/unemployment)

• Call center for clinical inquiries 24/7 (770-488-7100)
  o [https://www.cdc.gov/cdc-info/ask-cdc.html](https://www.cdc.gov/cdc-info/ask-cdc.html)

• Others
  o NIH COVID-19 Treatment Guidelines: [https://www.covid19treatmentguidelines.nih.gov/overview/](https://www.covid19treatmentguidelines.nih.gov/overview/)
Contact Tracing

- **External partners tools/resources**
  - **Association of State and Territorial Health Officials:** Making Contact: A Training for COVID-19 Contact Tracers Introductory Online Course: [https://learn.astho.org/p/ContactTracer](https://learn.astho.org/p/ContactTracer)
Appendix D: Guidance on Test Usage (Asymptomatic Populations and Serology)

Information on testing prioritization can be found here: [https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html](https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html)

**Testing asymptomatic populations**

Testing of asymptomatic individuals is a growing consideration as the role of asymptomatic and subclinical infections in transmission becomes more apparent. Emerging evidence suggests that asymptomatic infections may play an important role in the epidemiology of the disease. Nevertheless, it is important to define the circumstances where testing asymptomatic persons is likely to be helpful in controlling the COVID-19 pandemic. Effective testing programs will focus on (1) persons with an increased likelihood of infection and (2) settings with particularly vulnerable populations, including but not limited to the following:

- Contacts of known (symptomatic or asymptomatic) cases. This may include testing of contacts going back one to two weeks before the onset of symptoms, particularly contacts who work with vulnerable populations.
- Residents and staff of long-term care facilities. Periodic testing and sentinel surveillance in these settings may serve to detect outbreaks early in this setting, where devastating outbreaks are known to occur and to be associated with high rates of asymptomatic infection. CDC is updating guidance for surveillance in these settings [https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html).
- Other healthcare facility workers and first responders. Healthcare facilities may consider testing staff periodically, starting with staff in high traffic, high risk areas such as emergency departments.

**Serologic testing**

Serologic testing currently has little role in the diagnosis of acute disease but is already playing an important role in the response to the pandemic. The uses of serologic testing fall into two broad categories: serologic surveillance of populations and serologic testing of individuals for proof-of-prior infection.

**Serologic surveillance**


Serologic surveillance has the potential to provide a more complete picture of how much infection has occurred already in the United States. Case-based surveillance for anything with a wide spectrum of severity will always miss many cases, and its increasingly clear that a substantial proportion of SARS-CoV-2 infections are asymptomatic. To the degree that SARS-CoV-2 infection results in measurable antibodies, serologic testing will pick up any infection.

The purposes of serologic surveillance are the following:

- To provide a more complete estimate of the incidence of infection.
- To determine the proportion of the population that is already immune.
- To better understand transmission.
- To evaluate the impact of community mitigation measures.


**External serosurveys**

- CDC will support state, tribal, local, and territorial health authorities to plan and implement serosurveys in their populations with known prior exposure. Serial antibody tests, initial and confirmatory, will be used in all field studies to ensure enhanced positive predictive values.
Serologic testing of individuals for proof-of-prior infection (immunity)

While the lay public often mistakenly refers to this as “serologic surveillance”, it is fundamentally different and is at its core a clinical activity designed to guide decisions about specific individuals by determining whether or not they are already immune to the infection. Serologic testing may play a role in a back-to-work strategy provided it can be shown that serologic testing can reliably infer immunity. This immunity may not need to be absolute: protection against severe infection may be enough even if immunity against reinfection isn’t reliable or durable.

While there appears to be considerable public optimism that serologic testing will allow return to work without the need for PPE or other precautions, there are many unknowns at this early date that limit implementation of serology for this purpose:

- The correlates of immunity to SARS-CoV-2 are not known and there are few or no data to confirm that antibodies detected in serologic tests correlate with such immunity. Studies in the US military during the 1970s showed that reinfection with endemic coronaviruses occurred in the presence of low levels of antibodies. Nonetheless, most experts feel immunity from infection is likely at least in the short term.
- The performance characteristics of serologic assays are not yet known, although there is much work ongoing to define those characteristics. Typically, a well-performing single step serologic assay may be expected to have a specificity of 95% (sensitivity is a secondary concern here, although also important), which is likely not enough for this purpose, given the potential consequences of COVID-19. Combining two different tests will be critical for improving performance and should be part of any strategy to utilize serologic testing for “immunity” determinations.
- The current seroprevalence is likely to be highly variable. In New York City, for example, with one of the highest incidence rates in the country, a recent survey among customers of retail outlets found a seroprevalence of 22%. Preliminary data at CDC from remainder clinical specimens in the New York City area found about half that rate; in Western Washington, the preliminary rate was closer to 5%. This has two implications:
  - At best, the use of serologic testing for a back-to-work strategy would likely benefit fewer than 10% of the population currently.
  - In the setting of a relatively low seroprevalence, any serologic test would have to have excellent performance characteristics. If a test with 95% specificity were used in a population with a true seroprevalence of 5%, almost half all “positives” would be false-positive and not immune and therefore must include 2 serial tests to confirm all positive results.
- There is a need for high-level consensus on the role of serologic testing in a back-to-work policy. The stakes are high for such a policy, so that in addition to the scientific data, there is also a need to have political consensus on this issue. Consensus is also needed on a plan for how to provide documentation of that immunity, be it through federal- or state-based immunity registries, digital proof-of-immunity, or physical documentation such as “immunity certificates”.

Despite these limitations, continued interest in the use of serologic testing in a back-to-work policy is likely. In the meantime, CDC is doing the following:

- Working with NIH/NCI, FDA, and ASPR on evaluating the first panel of 25 serologic assays. More testing will quickly follow these tests.
- Designing studies to track healthcare workers long term to monitor for evidence of reinfection.
- Tracking seroprevalence nationally, as described above.
Appendix E: Assessing Surveillance and Hospital Gating Indicators

This document is for use by public health and government officials to aid their decisions when to reopen communities. It describes four indicators specific to disease occurrence and hospital readiness, which form part of the “gating criteria” described in the Opening Up America Again guidelines.

Background and Summary

On April 16, 2020, the White House released the Opening Up America Again guideline (https://www.whitehouse.gov/openingamerica/), which outlines a three-phased approach to relaxing community mitigation measures currently in place to limit transmission of the SARS-CoV-2 virus. The purpose of the guideline is to outline a path to re-opening the economy while mitigating the risk of resurgence in COVID-19 illnesses and protecting vulnerable populations. The phased approach can be implemented on a statewide basis or community-by-community at governors’ discretion. The guideline proposes the use of three categories of “gating” indicators (based on symptoms, based on cases, and for hospitals) to assess when to move through three community mitigation phases (Phase One, Phase Two, and Phase Three). Two gating indicators are in each category and include:

- **Indicators based on symptoms:**
  1. Downward trajectory of influenza-like illnesses (ILI syndrome) reported within a 14-day period
  AND
  2. Downward trajectory of COVID-like syndromic cases (i.e., COVID-like illness or CLI syndrome) reported within a 14-day period

- **Indicators based on cases:**
  3. Downward trajectory of documented COVID-19 cases within a 14-day period
  OR
  4. Downward trajectory of positive tests as a percent of total tests within a 14-day period (concurrent with a flat or increasing volume of tests)

- **Indicators for hospital readiness:**
  5. Capacity to treat all patients without utilization of crisis care standards
  AND
  6. Robust testing program in place for at-risk healthcare workers, including antibody testing

The Table at the end of the document summarizes all six indicators and the measures to support planning for transitioning through community mitigation phases. Indicators 1 through 4 rely on public health surveillance data to determine the trajectory of COVID-19 transmission within a jurisdiction. This document describes the measurement and interpretation of these four disease occurrence gating indicators. This document also highlights other disease occurrence measures that may be important for state or local jurisdictions to use when adjusting the intensity of community mitigation measures. Indicators 5 and 6 utilize hospital readiness measures to inform decision-making processes about readiness to move through mitigation phases. In addition to these indicators, CDC and CMS work collaboratively to provide guidance for reopening America. Further information on reopening of clinical facilities is available at https://www.cms.gov/files/document/covid-flexibility-reopen-essential-non-covid-services.pdf.
Disease Occurrence Gating Indicators

The following subsections provide further detail for each of the disease occurrence gating indicators outlined in the *Opening Up America Again* guideline, including a description and rationale, potential data sources, how to assess decreases (and moving through the three mitigation phases), how to assess increases (*i.e.*, “rebound”), and interpreting each measure’s strengths and limitations. Numerous data sources and surveillance systems exist at the local, state, and federal levels that can be used to measure and evaluate these indicators. Local and state officials should use the best data available, regardless of source, when assessing the trajectory of COVID-19 illnesses. Variability will exist from jurisdiction to jurisdiction in the quality, completeness, and timeliness of these data sources, and sufficient data may not be available for all jurisdictions to evaluate all four of the disease occurrence gating criteria. In situations where all the gating indicators cannot be assessed, additional data sources available locally may assist in determining the trajectory of COVID-19 activity in the jurisdiction.

**Downward trajectory of ILI reported within a 14-day period**

- **Description/Rationale:** ILI is a syndromic surveillance categorization applied to emergency department (ED) and outpatient visit symptom and diagnostic code data. This measure is intended to identify areas that are experiencing sustained decreases in outpatient clinic or ED visits in people with ILI. ILI is defined as fever with cough and/or a sore throat. COVID-19 may present with symptoms similar to ILI, so the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) and the National Syndromic Surveillance Program (NSSP) can be used to track COVID-19 trends, especially when paired with SARS-CoV-2 and other respiratory pathogen testing data.

- **Data Sources:** Outpatient care facilities and hospital EDs selected by state and/or local health departments for participation in the Outpatient Influenza-Like Illness Network (ILINet) report to CDC either directly or through their health department via a web-based reporting system. In addition, electronic data, including data from CDC’s NSSP can be uploaded to ILINet. These data are stored in a shared database for use by CDC and state/local public health officials. States and jurisdictions may collect syndromic surveillance data on ILI locally that is not submitted to ILINet but could be used in interpreting the ILI gating indicator. ILINet data is available publicly at the state-level at [https://www.cdc.gov/flu/weekly/fluviewinteractive.htm](https://www.cdc.gov/flu/weekly/fluviewinteractive.htm).

- **Assessing Decreases:**
  - To pass the criteria of a 14-day downward trajectory in ILI syndromic cases, a locality must either have experienced 14 days of decreasing cases or 14 days of minimal ILI activity. To determine a downward trajectory, the visits data are assessed using a smoothed curve to account for periodic fluctuations in ILI. To calculate this curve, CDC applies a cubic spline, or “smoothed curve”, a statistical method that smooths out day-to-day variability in the data. The slope of this curve is used to assess declining incidence. Localities must have 14 days of consecutive downward slope, allowing for 2-3-day grace periods of increasing ILI to allow for irregularities. It is recommended that localities assess both the total counts of ILI visits and ILI visits as a percentage of total ED visits. Statistical coding used by CDC (using the R package) can be shared with state and local jurisdictions upon request.
  - Normal variation in ILI ED and outpatient visits can affect the assessment of daily trends, especially in smaller geographies with low daily visits and by variations in healthcare seeking behavior associated with the day of the week, holidays, and current social distancing measures.
  - ILI activity levels are traditionally calculated for jurisdictions based on the percent of outpatient visits due to ILI in a jurisdiction compared with the average percent of ILI visits that occur during weeks with little or no influenza virus circulation in that jurisdiction (*i.e.*, non-influenza...
weeks), adjusted for the sites contributing data for the week. ILI activity values within two standard deviations of the non-influenza week mean are classified as a minimal level of ILI.

- Given potential changes in healthcare seeking behaviors resulting from community mitigation measures that can significantly affect the denominator of ILI proportions, jurisdictions should analyze within-jurisdiction ILI trends using both the number (count) and proportion of visits to account for this potential bias.

- **Mitigation Phase Transitions:** All the gating indicators as well as other information available locally should be used by jurisdictions when choosing to move through the community mitigation phases. Below is a framework for specifically evaluating whether the ILI gating indicator is met with respect to these phase transitions.
  
  - Transition into Phase One: achieve 14 consecutive days (or two weeks) of downward trajectory or maintaining minimal ILI activity level.
  - Transition into Phase Two: achieve an additional 14 consecutive days (or two weeks) of improvement (downward trajectory or minimal ILI activity level) without experiencing a rebound (defined below).
  - Transition into Phase Three: achieve another 14 consecutive days (or two weeks) of improvement (downward trajectory or minimal ILI activity level) without experiencing a rebound (defined below).

- **Identifying Rebound:**
  
  - An increase in ILI visits or an increase in ILI activity levels over 5 consecutive days may indicate a potential rebound in COVID-19 activity.

- **Interpretation/Limitations:**
  
  - ILI is a nonspecific syndromic measure and can be influenced by the circulation of numerous respiratory pathogens and should be interpreted in the context of virologic and other surveillance data. For example, ILI is expected to fluctuate in the fall and winter due to circulation of seasonal influenza.
  - The purpose of ILI surveillance is to detect changes in outpatient visits for febrile respiratory illness. The percent of patient visits for ILI can be affected by changes in health care seeking behavior, so jurisdictions should look at numbers (counts) of ILI visits in addition to proportions.
  - ILI frequency and activity levels within a jurisdiction are influenced by the mix of primary care practice types submitting data. These changes make direct comparisons of ILI from one jurisdiction to another invalid. Calculation of ILI activity levels allows for more appropriate comparison of ILI between jurisdictions.

*Downward trajectory of COVID-like illness (CLI) reported within a 14-day period*

- **Description/Rationale:** CLI is a syndromic surveillance categorization applied to ED visit symptom and diagnostic code data. This measure is intended to identify areas that are experiencing sustained decreases in ED visits consistent with the presenting symptoms of COVID-19 illness (fever and either cough, shortness of breath, or difficulty breathing) or with a coronavirus diagnostic code that fits CDC interim coding guidelines, and without a diagnostic code for influenza ([https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf](https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf)). CLI can be used to track COVID-19 trends, especially when paired with SARS-CoV-2 and other respiratory pathogen testing data.

- **Data Sources:** Hospitals report ED visits in near real-time to state and/or local health departments and to NSSP. These data are stored within the BioSense Platform where they can be analyzed and
exchanged by public health officials. States and jurisdictions may collect syndromic surveillance data on CLI locally that is not submitted to NSSP but could be useful for interpreting the CLI gating indicator.

- **Assessing Decreases:**
  - To pass the criteria of a 14-day downward trajectory in CLI syndromic cases, a locality must either have experienced 14 days of decreasing cases or exhibit near pre-pandemic levels of CLI. To determine a downward trajectory, the visits data are assessed using a smoothed curve to account for periodic fluctuations in CLI. To calculate this curve, CDC applies the cubic spline as with ILI and described above. The slope of this curve is used to assess declining incidence. Localities must have 14 days of consecutive downward slope, allowing for 2-3-day grace periods of increasing CLI to allow for irregularities. It is recommended that localities assess both the total counts of CLI visits and CLI visits as a percentage of total ED visits. Statistical coding used by CDC (using the R package) can be shared with state and local jurisdictions upon request.
  - Normal variation in CLI ED visits affects the assessment of daily trends, especially in smaller geographies with low daily visits and by variations in healthcare seeking behavior associated with the day of the week, holidays, and current social distancing measures.

- **Mitigation Phase Transitions:** All the gating indicators as well as other information available locally should be used by jurisdictions when choosing to move through the community mitigation phases. Below is a framework for specifically evaluating whether the CLI gating indicator is met with respect to these phase transitions.
  - Transition into Phase One: achieve 14 consecutive days of improvement (downward trajectory or near pre-pandemic CLI ED visits).
  - Transition into Phase Two: achieve an additional 14 consecutive days of improvement (downward trajectory or near pre-pandemic CLI ED visits) without experiencing a rebound (defined below).
  - Transition into Phase Three: achieve another 14 consecutive days of improvement (downward trajectory or near pre-pandemic CLI ED visits) without experiencing a rebound (defined below).

- **Identifying Rebound:** Two primary methods can be used to help assess for a rebound in CLI ED visits.
  - Within NSSP, daily statistical anomaly detection methods are automatically applied to time series trends, and anomalous increases are flagged for further epidemiologic investigation. Multiple consecutive days of anomalies may be an indicator of increases in COVID-19 activity and could be used to focus additional testing of patients.
  - Regression methods (e.g., binomial regression) can be used to classify time series trends in the last 15 days to detect 5-day periods of significant increase in patients being seen with CLI and can also be used to focus additional investigations and/or confirmatory testing.

- **Interpretation/Limitations:**
  - The purpose of syndromic surveillance is to find timely, more automated, indicators of a change in patterns of illness or health seeking behaviors in a community than is possible with case reporting. Syndromic data can initiate further confirmatory investigation. CLI is a nonspecific syndromic measure and could be influenced by the circulation of other respiratory pathogens.
  - The timeliest element of ED records is the patient chief complaint text describing their symptoms. The CLI syndrome is based in part on the patient’s chief complaint at presentation to the ED, which may or may not actually be COVID-19, but also includes visits that were assigned a COVID-19 diagnosis code.
• The data quality and completeness of chief complaint text and diagnostic codes can vary by reporting hospital and can affect the assessment of trends over time.

• In general, syndromic categorizations emphasize timeliness and sensitivity over specificity. As such, the CLI gating indicator may exhibit changes earlier than other indicators but may also include visits for other illnesses that have similar symptoms as COVID-19 (e.g., infections with other respiratory viruses). Interpretation of CLI data should always be considered in conjunction with other data and the local context. Data that track the presence of other respiratory illnesses (e.g., respiratory syncytial virus and influenza) circulating within the community may help in assessing whether CLI is due to the virus that causes COVID-19 or other viruses.

Downward trajectory of documented (confirmed and probable) cases within a 14-day period

• **Description/Rationale:** On April 5, 2020, the Council of State and Territorial Epidemiologists (CSTE) issued an interim COVID-19 position statement making COVID-19 a nationally notifiable disease and establishing confirmed and probable case definitions (www.cste.org/resource/resmgr/2020ps/interim-20-id-01_covid-19.pdf). The case report gating indicator is intended to identify communities experiencing sustained decreases in the number of new cases occurring each day, an indication of decreases in disease transmission.

• **Data Sources:** Case report information for confirmed and probable cases collected by state and local jurisdictions and submitted to CDC; publicly available aggregated case count data (e.g., USAFacts: https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/); US Census population estimates (used as denominator for incidence calculations)

• **Assessing criteria for reduction in number of cases:** To pass this criterion, a locality must either 1) have experienced 14 days of decreasing cases or 2) be in a low-incidence plateau. A locality that has a new outbreak or rebound cannot advance to the next phase unless they see another 14 days of decline.

• **Defining 14 days of decreasing cases:** To assess a downward trajectory, CDC uses a 3-day rolling average and applies a spline curve (described above). A period of 14 days of declining cases occurs when fewer cases are reported at the end of the 14 days compared with the number at the beginning of the period, using the 3-day rolling average fitted with the spline curve to define the number of cases. In addition, a “grace period” of 5 days may be applied during a downward trajectory, during which cases may increase for no more than 5 consecutive days. (If 5 days of consecutive increase occur, then the jurisdiction has met the criteria for rebound and is no longer in a downward trajectory.) Statistical coding used by CDC (using the R package) can be shared with state and local jurisdictions upon request.

  • **Defining a low incidence plateau**
    - A low-incidence plateau is defined as a very low number of new cases reported (below 10 cases per 100,000 population over 2 weeks) with only minimal change in daily cases.
    - To qualify for this category, a locality must previously have seen elevated case counts.

  • **Mitigation Phase Transitions:** All the gating indicators as well as other information available locally should be used by jurisdictions when choosing to move through the community mitigation phases. Below is a framework for specifically evaluating whether the case report gating indicator is met with respect to these phase transitions. Note that the Opening Up America Again guideline specifies that either the case report gating indictor or the percent positive gating indicator should be met.

    • Transition into Phase One: achieve 14 consecutive days of improvement (downward trajectory or near-zero incidence).
    • Transition into Phase Two: achieve an additional 14 consecutive days of improvement (downward trajectory or near-zero incidence) without experiencing a rebound (defined below).
• Transition into Phase Three: achieve another 14 consecutive days of improvement (downward trajectory or near-zero incidence) without experiencing a rebound (defined below).

• Defining rebound
  • A rebound occurs when the smoothed, 3-day average of case counts exhibits an increase over a 5 consecutive day period, following a downward trajectory of 14 or more days, including any grace period applied.

• Interpretation/Limitations:
  • Case report data are a lagging indicator for assessing SARS-CoV-2 transmission in the community, as new cases are not identified until after the incubation period occurs, the ill person seeks testing or healthcare for their illness, and the information is reported to health officials.
  • The choice of the dates used (e.g., onset date, report date) is critical in the interpretation of observed trends. If available, onset date is preferred because it improves timeliness of trend interpretation. However, because date of report is more likely to be available than date of illness onset, it is more frequently the date used to calculate trends. Whatever date is used, the assessment must account for the fact that very recent cases will not have been reported. Excluding recent onset dates or report dates (e.g., in the last 3 days or last week if onset dates are used) from assessment of trends should be considered to ensure that incomplete reporting of recent cases does not give the false appearance of downward trajectory.
  • CDC analyses are typically based on the date of case report and not diagnosis or onset date because it is the most uniformly available date across jurisdictions. Preliminary analyses of national data show that there is typically a 8- to 10-day lag between the date of symptom onset and the date the case is reported to CDC, but this varies by jurisdiction.
  • A sustained downward trajectory demonstrates improvement in daily case incidence but does not necessarily equate to a low disease burden. Communities should consider local resource capacity (e.g., availability of public health staff to conduct contact tracing) when determining appropriate incidence thresholds for making phase transition decisions.

Downward trajectory of positive tests as a percent of total tests within a 14-day period with stable or increasing test volume

• Description/Rationale: Laboratory test percent positive can be used in combination with, or as an alternative to, observing a decline in new case reports. In circumstances where testing is adequate and testing practices are largely stable, percent positive may be a reliable indicator of COVID-19 activity.

• Data Sources: Positive and negative SARS-CoV-2 test results reported by laboratories to state health departments. Data from the Census Bureau’s Population Estimates Program can be used to estimate state and county population denominators for per-capita test rates.

• Assessing Decreases:
  • Percent positive is calculated as the number of positive tests divided by the total test results, with total test results defined as the sum of positive tests and negative tests, excluding records where the test was not performed because the specimen was not usable or the test was cancelled. The number of tests with indeterminate results has been small, so not including these in the denominator of total test results should not affect interpretation of the trends observed.
  • A jurisdiction must see a 14-day downward trajectory in percent positive (or near-zero percent positive) with up to 2-3 consecutive days of increasing or stable percent positive allowed as a grace period if data are inconsistent, while total test volume is stable or increasing.
• Methods to assess decreases in laboratory test positivity are similar to those used to assess decreases in ILI and CLI.

• **Mitigation Phase Transitions:** All the gating indicators as well as other information available locally should be used by jurisdictions when choosing to move through the community mitigation phases. Below is a framework for specifically evaluating whether the percent positive gating indicator is met with respect to these phase transitions. Note that in the *Opening Up America Again* guideline, the case report gating indicator or the percent positive gating indicator should be met.
  
  • Transition into Phase One: achieve 14 or more consecutive days of decline in percent positive (or near-zero percent positive) while total test volume is stable or increasing.
  • Transition into Phase Two: achieve an additional 14 or more consecutive days of decline in percent positive (or near-zero percent positive) while total test volume is stable or increasing.
  • Transition into Phase Three: achieve an additional 14 or more consecutive days of decline in percent positive (or near-zero percent positive) while total test volume is stable or increasing.
  • If a near-zero plateau has been reached, can meet if plateau is maintained over 14 consecutive days (2-3-day grace period)

• **Identifying Rebound:** Multi-day increases in percent positivity with stable or increasing testing volume should be assessed along with case report and CLI data to identify rebounds.

• **Interpretation/Limitations:**
  
  • The daily percent positive may fluctuate, particularly in areas with smaller populations. Total test volume may also vary by day of the week, based on the number of tests ordered or regular system maintenance at laboratories.
  
  • The percent positive is driven by the number of people who are positive in a community and the number of people who are tested. Declines in percent positive may result from an expansion of testing to more people. Thus, it is important to track percent positive in combination with the number tested, whether measured as the total volume of all test results, or as total test results per capita. Percent positivity should only be used as an indicator of COVID-19 activity when per capita testing levels are stable over the time period being assessed.
  
  • The percent positive may also be affected by a changing proportion of tests in people who are less likely to be infected, such as those who are asymptomatic or who have less severe symptoms. Few laboratories have fields indicating whether the person tested was asymptomatic or whether the patient was in an inpatient or outpatient setting at the time of testing. However, communities can stratify by data source to assess changes in the population tested over time, such as tracking the percent positive in hospital data separately from the percent positive in large commercial laboratories.
  
  • The residence of the person tested may not be validated as thoroughly in laboratory data as in case data. Patient zip code may be based on insurance billing data, and thus less likely to be complete and correct when the person tested is uninsured or on another family member’s plan.
  
  • Provider zip code is generally accurate, when available. However, drive-up facilities might use a central zip code that does not reflect where the physical drive-up facility is located.

*Joint interpretation of all four disease occurrence gating criteria*

The four disease occurrence gating indicators should be interpreted collectively to reach a determination on the trajectory of COVID-19 activity within a jurisdiction, bearing in mind that the measures differ significantly in their lag, specificity, and sensitivity. Lab testing and syndromic data sources generally have less lag than COVID-19 case report data relative to when transmission occurred. SARS-CoV-2 testing and COVID-
19 case reports are more specific measures of COVID-19 activity than the CLI syndrome, but all three are likely far more specific than the ILI syndrome. The CLI syndrome likely has superior sensitivity to the other measures, as it is more likely to capture people with COVID-19 that were not tested. While downward trajectory for a period of 14 days is used for each of the disease occurrence gating indicators in the Opening Up America Again guideline, state and local jurisdictions should use judgment based on their knowledge of local disease surveillance practices and infrastructure in determining whether longer time periods (e.g., 21 or 28 days) are needed before moving to different community mitigation phases.

Other Data Sources and Measures

The four disease occurrence gating indicators above provide insight into both the intensity and trajectory of the COVID-19 pandemic within jurisdictions. In addition, other epidemiologic data sources are available to local, state, and federal health officials and can be used to confirm trends observed in the disease occurrence gating indicators.

- **COVID-19 hospital admissions**: Depending on the overall COVID-19 incidence rate, the size of the jurisdiction, and the regional hospital referral patterns, hospitalizations for laboratory-confirmed COVID-19 can be an important measure to assess trajectory. Testing is likely more complete and less variable in hospitalized populations, providing more assurance that observed trends are not driven by testing practices. In addition to helping verify increases or decreases in the disease occurrence gating indicators, monitoring COVID-19 hospital admissions (and discharges) can help assess the burden on local healthcare capacity.

- **COVID-19 deaths**: Depending on the overall COVID-19 incidence rate and the size of the jurisdiction, deaths due to COVID-19 may occur in high enough numbers to reliably assess the trajectory of the outbreak in the jurisdiction. Although they represent a small proportion of all COVID-19 illnesses and significantly lag the core disease occurrence gating indicators, vital records are a universally collected data source and should be available for review in all jurisdictions. Further, observing declines in newly reported COVID-19 deaths almost certainly indicates that demands on the healthcare system are waning. Care should be taken to understand the extent and variability in SARS-CoV-2 testing for deceased individuals in the jurisdiction when using death as a source of data to understand the overall trajectory of COVID-19 illnesses in the jurisdiction. COVID-19 death data reported to CDC’s National Center for Health Statistics are published weekly by state (https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm).

- **Measures of trajectory**: The effective reproductive number (the average number of secondary cases from an infectious case in an a particular population at a specific point in time) and doubling time (the time required for the number of cases to double) are epidemiologic measures that can be used to characterize the speed with which illnesses are spreading in an outbreak. Although these measures can be imprecise, especially when calculated within smaller populations, they provide alternative ways to analyze and characterize the trajectory of COVID-19 activity.

Implied in the Core State Preparedness Responsibilities in the Opening Up America Again guideline is the need for jurisdictions to have confidence in the epidemiologic data being used to make assessments about the magnitude and trajectory of COVID-19 illnesses. In order for most of the gating indicators to be reliably assessed, 1) rapid testing should be occurring as indicated for all clinical, public health, and infection prevention needs and 2) all new symptomatic COVID-19 cases in the jurisdiction should be able to be rapidly identified through active surveillance of laboratories and healthcare facilities. In the absence of widespread testing and robust active surveillance, jurisdictions should be cautious when adjusting mitigation strategies based on the
disease occurrence gating indicators. Several measures, listed below, can be helpful in providing an indirect assessment of the completeness of case ascertainment in a jurisdiction.

- **COVID-19 case-fatality ratio**: Case-fatality is defined as the proportion of COVID-19 cases result in death. Although estimates of the percentage of symptomatic COVID-19 illnesses that result in death has varied widely, the overall percentage is likely lower than 1-2%. Although many factors contribute to disease severity, including the underlying health status of the population, jurisdictions that have very high COVID-19 case-fatality ratios (above 5-10%) may be under-ascertaining COVID-19 illnesses. This could indicate that case reporting is an unreliable measure of true COVID-19 activity. In this situation it may be useful to examine measures for CLI syndrome or COVID-19 hospital admissions as measures of disease activity.

- **High percent positive**: Although changes in percent positive is an indicator in the *Opening Up America Again* guideline, very high proportions of SARS-CoV-2 positivity (e.g., >25%) may be an indicator that testing levels are not adequate and that COVID-19 illnesses are being under-ascertained in the jurisdiction, as it suggests that only a limited number of people with a high likelihood of being infected with SARS-CoV-2 are able to be tested. In this situation it also may useful to look at the CLI syndrome or at COVID-19 hospital admissions as measures of disease activity, since they are likely less susceptible to the influence of testing availability.

- **Per capita testing**: It is difficult to determine a widely applicable benchmark for a per capita level of SARS-CoV-2 testing that is sufficient to have confidence in the adequacy of COVID-19 case-ascertainment. However, jurisdictions can consider evaluating their per capita testing to assist in judging whether testing levels are adequate for effective COVID-19 surveillance.

- **Proportion of cases with an unknown source**: Improvements in case ascertainment and contact tracing should lead to a lower proportion of new cases with an unknown exposure to SARS-CoV-2. Jurisdictions can consider tracking the proportion of new COVID-19 cases without a documented exposure source (e.g., travel to a high-incidence region or country, exposure to someone with a confirmed case of COVID-19, attending and event or going to a setting with suspected SARS-CoV-2 transmission). Although difficult to achieve, jurisdictions that have fewer than 50% of new cases with an unknown exposure source likely have likely achieved high levels of case ascertainment, interviewing, and contact tracing.

### Hospital Indicators

**Capacity to treat all patients without crisis care**

- **Description/Rationale**: Capacity indicators, including percentage of inpatients and ICU beds occupied and PPE supplies, help identify areas where additional healthcare capacity needs may exist now or in the future.

- **Data sources**: Data within HHS Protect, including from CDC’s National Healthcare Safety Network (NHSN) (a healthcare infection associated tracking system), provide information on inpatient and ICU bed occupancy, staffing shortages, and PPE supplies.

- **Assessing indicator**: All three measures of treating patients without crisis care should be met before a jurisdiction moves to the next community mitigation phase.

- **Mitigation Phase Transitions**: All the gating indicators as well as other information available locally should be used by jurisdictions when choosing to move through the community mitigation phases. Below is a framework for specifically evaluating whether the hospital indicators are met with respect to these phase transitions.
• Transition into Phase One: Inpatient and ICU beds <80% full for 7 consecutive days AND no staff shortages for 7 consecutive days AND PPE supplies adequate and available for >4 days.
• Transition into Phase Two: Inpatient and ICU beds <75% full for 7 consecutive days AND no staff shortages for 7 consecutive days AND PPE supplies adequate and available for >4 days.
• Transition into Phase Three: Inpatient and ICU beds <70% full for 7 consecutive days AND no staff shortages for 7 consecutive days AND PPE supplies adequate and available for >15 days.

**Interpretation/Limitations:**
• Hospitals within the same jurisdiction may be at different stages with regard to these measures. Public health officials should assess the status of the jurisdiction’s hospital capacity overall and consider whether resources (e.g., clinical staff, PPE) could be re-allocated to address differential needs.

**Robust testing program**

**Description/Rationale:**
• The percentage of positive diagnostic tests for SARS-CoV-2 can be used as an indirect measure of agreement between testing demand and test availability. A target frequency of negative tests (e.g., 80% negative) must be established as an indicator of “adequate” availability of tests. This threshold can then be used to monitor for regional shortages and target distribution of testing resources to areas with greatest need.
• Timeliness of results is another measure of laboratory testing capacity, and prompt results are essential for effective contact tracing.

**Data sources:** Positive and negative SARS-CoV-2 test results reported by laboratories to state health departments. Median time between test order and results can be calculated from the reported laboratory data.

**Assessing indicator:** Both criteria for a robust testing program should be met before a jurisdiction moves to the next community mitigation phase. The metric for percentage positive tests can be assessed as the percentage of positive of viral tests among all tests with a result for 14 consecutive days. An alternative would be to have daily percent positive below the phase transition threshold for 14 consecutive days.

**Mitigation Phase Transitions:** All the gating indicators as well as other information available locally should be used by jurisdictions when choosing to move through the community mitigation phases. Below is a framework for specifically evaluating whether the indicators for a robust testing program are met with respect to these phase transitions.
• Transition into Phase One: Percentage positive tests ≤20% for 14 days AND median time from test order to result ≤4 days.
• Transition into Phase Two: Percentage positive tests ≤15% for 14 days AND median time from test order to result ≤3 days.
• Transition into Phase Three: Percentage positive tests ≤10% for 14 days AND median time from test order to result ≤2 days.

**Interpretation/Limitations:**
• This indicator refers to tests for current infection (e.g., nucleic acid (PCR) or antigen tests). Serology (i.e., antibody) testing metrics should not be used for this indicator.
• Lags in test reporting may lead to incomplete data for calculating percent positive tests for the most recent few days. Jurisdictions should calculate percent positive for the most recent 14 days with near-complete testing data.
Additional Considerations

Overall Incidence Level

The disease occurrence gating indicators all pertain to assessing the trajectory of COVID-19 activity, but do not specify that COVID-19 incidence should reach an absolute level to move through the mitigation phases. Jurisdictions should be cautious in pivoting from a general community mitigation approach back toward an identification and containment approach until incidence is low enough and resources adequate to 1) attempt an initial interview for nearly all new COVID-19 cases within one day of health department notification, 2) to rapidly isolate all newly identified COVID-19 cases, and 3) to initiate appropriate follow up (isolation, self-monitoring, and rapid testing of symptomatic contacts) for nearly all identified contacts of newly identified cases. Incidence should also be low enough that health departments can respond to large outbreaks (e.g., nursing home outbreaks) that require substantial resources to investigate and control. Declines in incidence should also be enough for healthcare capacity to not only meet current demands, but to be able to comfortably surge in the event of an increase in cases (e.g., availability of acute care beds, critical care beds, ventilators, and adequate PPE).

Special Populations and Settings

Infections in high-risk settings and populations can disproportionately impact localized transmission and the ability of public health capacity to keep pace with follow up needs such as contract tracing and screening. Efforts should be taken to monitor infections in some specific populations and settings, including but not limited to healthcare personnel, patients in healthcare facilities (e.g., nursing homes, dialysis centers, long term care facilities), and residents of congregate living settings (e.g., prisons, youth homes, shelters). In addition, identification of illnesses at work places (e.g., meat and poultry processing facilities) or events with the potential for “explosive spread” (e.g., mass gatherings) may warrant adjustment of community mitigation measures in the absence of community-wide changes in the disease occurrence gating indicators.

Neighboring Jurisdictions

When making decisions about adjusting community mitigation measures, state and local jurisdictions also should coordinate with officials in neighboring areas to assess the burden and trajectory of COVID-19 illnesses in the surrounding region. Neighboring or nearby jurisdictions with significantly higher incidence or with increasing COVID-19 activity could reintroduce SARS-CoV-2 to a jurisdiction, jeopardizing improvements within the jurisdiction.

Measures of Mobility and Social Distancing

If available, it may be important to understand the knowledge, attitudes and behaviors of the community as it relates to the public health guidance provided within the local jurisdiction. Survey data and data on mobility can be useful in understanding if community members are aware of and following established social distancing and isolation guidelines and informing changes in the mitigation strategies used. Several publicly available data sources currently exist that generate measures of social distancing and mobility, frequently based on mobile phone location services or social media data.

Summary

The disease occurrence gating indicators in the Opening Up America Again guideline provide states and communities insight into the trajectory of the COVID-19 pandemic in their jurisdiction. The disease occurrence gating indicators should be evaluated collectively, considering their relative strengths and weaknesses, in the context of other epidemiologic data available for the jurisdiction. The hospital indicators are designed to help
decision makers understand the health system’s ability to handle a potential surge in cases. These indicators are part of the broad assessment jurisdictions should undertake when deciding when and how to adjust community mitigation strategies for COVID-19.

<table>
<thead>
<tr>
<th>Gating</th>
<th>Threshold for entering</th>
<th>Threshold for entering</th>
<th>Threshold for entering</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Criteria</strong></td>
<td><strong>Phase 1</strong></td>
<td><strong>Phase 2</strong></td>
<td><strong>Phase 2</strong></td>
</tr>
<tr>
<td><strong>Decreases in ED and/or outpatient visits for influenza-like illness (ILI)</strong></td>
<td>Downward trajectory of ILI/CLI (or minimal ILI activity or near pre-pandemic level of CLI ED visits) reported over a 14-day period</td>
<td>Downward trajectory of ILI/CLI (or minimal ILI activity or near pre-pandemic level of CLI ED visits) reported for at least 14 days after entering Phase 1 without experiencing a rebound</td>
<td>Downward trajectory of ILI/CLI (or minimal ILI activity or near pre-pandemic level of CLI ED visits) reported for at least an additional 14 days after entering Phase 2 without experiencing a rebound</td>
</tr>
<tr>
<td><strong>Decreases in ED and/or outpatient visits for COVID-like illness (CLI)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uses a 3-day average in a cubic smoothing spline</td>
<td>Same criteria but for a second 14-day period</td>
<td>Same criteria but for a second 14-day period</td>
</tr>
<tr>
<td></td>
<td>14 consecutive days of decline required but can use a 2 – 3 day grace period if data are inconsistent</td>
<td>Rebound is determined if the trajectory increases in a 5-day period</td>
<td>Rebound is determined if the trajectory increases in a 5-day period</td>
</tr>
<tr>
<td></td>
<td>Look at both total visits for ILI/CLI and percentage of visits for ILI/CLI</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14th day must be lower than 1st day</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>If near pre-pandemic level of CLI ED visits has been reached, can meet if pre-pandemic level is maintained over 14 consecutive days (2-3 day grace period)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreases in newly identified COVID-19 cases</td>
<td>Downward trajectory (or near-zero incidence) of documented cases over a 14-day period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Uses a 3-day average in a cubic smoothing spline</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 14 consecutive days of decline required but can use up to a 5-day grace period if</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>data are inconsistent</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 14th day must be lower than 1st day</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To be near-zero incidence, must have fewer than 10 cases per 100k population</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>over 14 days and must have previously had elevated cases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Downward trajectory (or near-zero incidence) of documented cases for at least 14 days after entering Phase 1

- Same criteria as Phase 1 for another 14 days
- Rebound is defined as having 5 consecutive days of increase

<table>
<thead>
<tr>
<th>Decreases in newly identified COVID-19 cases</th>
<th>Downward trajectory (or near-zero incidence) of positive tests as a percent of total tests for at least 14 days after entering Phase 2 (flat or increasing volume of tests)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Uses a 3-day average in a cubic smoothing spline</td>
</tr>
<tr>
<td></td>
<td>• 14 consecutive days of decline required but can use up to a 5-day grace period if data are inconsistent</td>
</tr>
<tr>
<td></td>
<td>• 14th day must be lower than 1st day</td>
</tr>
<tr>
<td></td>
<td>• To be near-zero incidence, must have fewer than 10 cases per 100k population over 14 days and must have previously</td>
</tr>
<tr>
<td></td>
<td>had elevated cases</td>
</tr>
</tbody>
</table>

### Downward trajectory (or near-zero incidence) of positive tests as a percent of total tests for at least 14 days after entering Phase 2

- Same criteria as Phase 2 for another 14 days
- Rebound is defined as having 5 consecutive days of increase

### Rebound

- Defined as having multi-day increases in percent positivity with stable or increasing testing volume.
- Look at positive results and cases
<table>
<thead>
<tr>
<th>Decreases in percentage of SARS-CoV-2 tests positive</th>
<th>10 cases per 100k population over 14 days) and must have previously had elevated cases</th>
<th>• Look at positive results and cases when assessing for rebound</th>
<th>when assessing for rebound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Downward trajectory (or near-zero percent positive) of positive tests as a percent of total tests over a 14-day period (flat or increasing volume of tests)</td>
<td>• Divide total positive results by total positive + negative&lt;br&gt;• Remove incomplete and inconclusive results&lt;br&gt;• 14 consecutive days of downward trend with up to 2-3 consecutive days of a grace period due to data inconsistency&lt;br&gt;• 14th day must be lower than 1st day&lt;br&gt;• If a near-zero plateau has been reached, can meet if plateau is maintained over 14 consecutive days (2-3 day grace period)&lt;br&gt;• Test volume must remain the same</td>
<td>Downward trajectory (or near-zero percent positive) of positive tests as a percent of total tests for 14 days after entering Phase 1 (flat or increasing volume of tests)</td>
<td>• Same criteria as Phase 1 for another 14 days&lt;br&gt;• Rebound is defined as having multi-day increases in percent positivity with stable or increasing testing volume.&lt;br&gt;• Look at positive results and cases when assessing for rebound</td>
</tr>
<tr>
<td>Downward trajectory (or near-zero percent positive) of positive tests as a percent of total tests for at least 14 days after entering Phase 2 (flat or increasing volume of tests)</td>
<td>• Same criteria as Phase 1 for another 14 days&lt;br&gt;• Rebound is defined as having multi-day increases in percent positivity with stable or increasing testing volume.&lt;br&gt;• Look at positive results and cases when assessing for rebound</td>
<td>• Test volume must remain the same</td>
<td></td>
</tr>
</tbody>
</table>
**Treat all patients without crisis care**
- Jurisdiction inpatient & ICU beds <80% full
- Staff shortage in last week = no
- PPE supplies adequate for >4 days

**Robust testing program**
- Test availability such that % positive tests ≤ 20% for 14 days
- Median time from test order to result ≤ 4 days

<table>
<thead>
<tr>
<th>Jurisdiction inpatient &amp; ICU beds &lt;75% full</th>
<th>Jurisdiction inpatient &amp; ICU beds &lt;70% full</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staff shortage in last week = no</td>
<td>Staff shortage in last week = no</td>
</tr>
<tr>
<td>PPE supplies adequate for &gt;4 days</td>
<td>PPE supplies adequate for &gt;15 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test availability such that % positive tests ≤ 15% for 14 days</th>
<th>Test availability such that % positive tests ≤ 10% for 14 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median time from test order to result ≤ 3 days</td>
<td>Median time from test order to result ≤ 2 days</td>
</tr>
</tbody>
</table>
Appendix F: Setting Specific Guidance

CDC offers this interim guidance to assist establishments as they open. CDC will update this guidance as it learns more about COVID-19 and best practices to prevent its spread.

This guidance is meant to supplement the decision tools CDC released on May 14, 2020. It lists specific practices that employers may find helpful at particular stages of the COVID-19 outbreak. This guidance sets forth a menu of safety measures, from which establishments may choose those that make sense for them in the context of their operations and local community, as well as State and local regulations and directives.

INTERIM GUIDANCE FOR CHILD CARE PROGRAMS

The gradual scale up of activities towards pre-COVID-19 operating practices at child care programs is crucial to helping parents and guardians return to work. Many states have closed schools for the academic year and, with summer quickly approaching, an increasing number of working parents may need to rely on these programs. CDC’s Interim Guidance for Administrators of US K-12 Schools and Child Care Programs and supplemental Guidance for Child Care Programs that Remain Open provide recommendations for operating child care programs in low, moderate, and significant mitigation communities. In communities that are deemed significant mitigation areas by state and local authorities, child care programs should be closed. However, child care programs can choose to remain open to serve children of essential workers, such as healthcare workers. All decisions about following these recommendations should be made locally, in collaboration with local health officials who can help determine levels of COVID-19 community transmission and the capacities of the local public health system and healthcare systems.

CDC is releasing this interim guidance, laid out in a series of three steps, to inform a gradual scale up of operations. The scope and nature of community mitigation suggested decreases from Step 1 to Step 3. Some amount of community mitigation is necessary across all steps until a vaccine or therapeutic drug becomes widely available.

Scaling Up Operations

- **In all Steps:**
  - Establish and maintain communication with local and State authorities to determine current mitigation levels in your community.
  - Protect and support staff, children, and their family members who are at higher risk for severe illness.
  - Provide staff from higher transmission areas (earlier Step areas) telework and other options as feasible to eliminate travel to childcare programs in lower transmission (later Step) areas and vice versa.
  - Follow CDC’s supplemental Guidance for Child Care Programs that Remain Open.
  - Encourage any other community groups or organizations that use the child care facilities also follow this guidance.
- **Step 1:** Restrict to children of essential workers.
- **Step 2:** Expand to all children with enhanced social distancing measures.
- **Step 3:** Remain open for all children with social distancing measures.
Safety Actions

Promote healthy hygiene practices (Steps 1-3)

- Teach and reinforce washing hands and covering coughs and sneezes among children and staff.
- Teach and reinforce use of cloth face coverings among all staff. Face coverings are most essential at times when social distancing is not possible. Staff should be frequently reminded not to touch the face covering and to wash their hands frequently. Information should be provided to all staff on proper use, removal, and washing of cloth face coverings.
- Have adequate supplies to support healthy hygiene behaviors, including soap, hand sanitizer with at least 60 percent alcohol (for staff and older children who can safely use hand sanitizer), paper towels, and tissues.
- Post signs on how to stop the spread of COVID-19, properly wash hands, promote everyday protective measures, and properly wear a face covering.

Intensify cleaning, disinfection, and ventilation (Steps 1-3)

- Clean, sanitize, and disinfect frequently touched surfaces (for example, playground equipment, door handles, sink handles, drinking fountains) multiple times per day and shared objects between use.
- Avoid use of items (for example, soft or plush toys) that are not easily cleaned, sanitized, or disinfected.
- Ensure safe and correct application of disinfectants and keep products away from children.
- Ensure that ventilation systems operate properly and increase circulation of outdoor air as much as possible such as by opening windows and doors. Do not open windows and doors if doing so poses a safety or health risk (for example, allowing pollens in or exacerbating asthma symptoms) to children using the facility.
- Take steps to ensure that all water systems and features (for example, drinking fountains or decorative fountains) are safe to use after a prolonged facility shutdown to minimize the risk of Legionnaires’ disease and other diseases associated with water.

Promote social distancing

- Steps 1 and 2
  - Ensure that classes include the same group of children each day and that the same child care providers remain with the same group each day, if possible.
  - Restrict mixing between groups.
  - Cancel all field trips, inter-group events, and extracurricular activities (Step 1).
  - Limit gatherings, events, and extracurricular activities to those that can maintain social distancing, support proper hand hygiene, and restrict attendance of those from higher transmission areas (Step 2; Note: restricting attendance from those in Step 1 areas).
  - Restrict nonessential visitors, volunteers, and activities involving other groups at the same time.
  - Space out seating and bedding (head-to-toe positioning) to six feet apart if possible.
  - Close communal use spaces, such as game rooms or dining halls, if possible; if this is not possible, stagger use and disinfect in between uses.
• If a cafeteria or group dining room is typically used, serve meals in classrooms instead. Put each child’s meal on a plate, to limit the use of shared serving utensils and ensure the safety of children with food allergies.
• Stagger arrival and drop-off times or put in place other protocols to limit direct contact with parents as much as possible.

• Step 3
  • Consider keeping classes together to include the same group of children each day, and consider keeping the same child care providers with the same group each day.
  • Allow minimal mixing between groups. Limit gatherings, events, and extracurricular activities to those that can maintain social distancing, support proper hand hygiene, and restrict attendance of those from higher transmission areas (Step 1 or 2 areas).
  • Continue to space out seating and bedding (head-to-toe positioning) to six feet apart, if possible.
  • Consider keeping communal use spaces closed, such as game rooms, playgrounds, or dining halls, if possible; if this is not possible, stagger use and disinfect in between uses.
  • Consider continuing to plate each child’s meal, to limit the use of shared serving utensils and ensure the safety of children with food allergies.
  • Consider limiting nonessential visitors, volunteers, and activities involving other groups. Restrict attendance of those from higher transmission areas (Step 1 or 2 areas).
  • Consider staggering arrival and drop-off times or putting in place other protocols to limit close contact with parents or caregivers as much as possible.

• Limit sharing (Steps 1-3)
  • Keep each child’s belongings separated and in individually labeled storage containers, cubbies, or areas and taken home each day and cleaned, if possible.
  • Ensure adequate supplies to minimize sharing of high-touch materials to the extent possible (art supplies, equipment etc. assigned to a single child) or limit use of supplies and equipment by one group of children at a time and clean and disinfect between use.
  • If food is offered at any event, have pre-packaged boxes or bags for each attendee instead of a buffet or family-style meal.
  • Avoid sharing of foods and utensils.
  • Avoid sharing electronic devices, toys, books, other games, and learning aids.
  • Prevent risk of transmitting COVID-19 by avoiding immediate contact (such as shaking or holding hands, hugging, or kissing).

• Train all staff (Steps 1-3)
  • Train all staff in the above safety actions. Consider conducting the training virtually, or, if in-person, ensure social distancing is maintained.

Monitoring and Preparing
Check for signs and symptoms (Steps 1-3)

• Screen children upon arrival, if possible. Establish routine, daily health checks on arrival, such as temperature screening of both staff and children. Options for daily health check screenings for children are provided in CDC’s supplemental Guidance for Child Care Programs that Remain Open and in CDC’s General Business FAQs for screening staff.
• Implement health checks (e.g. temperature checks and symptom screening) safely and respectfully, and with measures in place to ensure confidentiality as well as in accordance with any applicable privacy laws or regulations. Confidentiality should be maintained.
• Employers and child care directors may use examples of screening methods in CDC’s supplemental Guidance for Child Care Programs that Remain Open as a guide.
• Encourage staff to stay home if they are sick and encourage parents to keep sick children home.

Plan for when a staff member, child, or visitor becomes sick (Steps 1-3)

• Identify an area to separate anyone who exhibits COVID-like symptoms during hours of operation, and ensure that children are not left without adult supervision.
• Establish procedures for safely transporting anyone sick to their home or to a healthcare facility, as appropriate.
• Notify local health officials, staff, and families immediately of any possible case of COVID-19 while maintaining confidentiality consistent with the Americans with Disabilities Act (ADA) and other applicable federal and state privacy laws.
• Close off areas used by any sick person and do not use them until they have been cleaned. Wait 24 hours before you clean or disinfect to reduce risk to individuals cleaning. If it is not possible to wait 24 hours, wait as long as possible. Ensure safe and correct application of disinfectants, and keep disinfectant products away from children
• Advise sick staff members or children not to return until they have met CDC criteria to discontinue home isolation.
• Inform those who have had close contact to a person diagnosed with COVID-19 to stay home and self-monitor for symptoms, and to follow CDC guidance if symptoms develop. If a person does not have symptoms follow appropriate CDC guidance for home isolation.

Maintain healthy operations (Steps 1-3)

• Implement flexible sick leave policies and practices, if feasible.
• Monitor absenteeism to identify any trends in employee or child absences due to illness. This might indicate spread of COVID-19 or other illness. Have a roster of trained back-up staff in order to maintain sufficient staffing levels.
• Designate a staff person to be responsible for responding to COVID-19 concerns. Employees should know who this person is and how to contact them.
• Create a communication system for staff and families for self-reporting of symptoms and notification of exposures and closures.
• Support coping and resilience among employees and children.

Steps 1-3

• It is very important to check State and local health department notices daily about spread of COVID-19 in the area and adjust operations accordingly.
• Where a community is deemed a significant mitigation community, child care programs should close, except for those caring for the children of essential workers, such as the children of health care workers.
• In the event a person diagnosed with COVID-19 is determined to have been in the building and poses a risk to the community, programs may consider closing for a few days for cleaning and disinfection.
INTERIM GUIDANCE FOR SCHOOLS AND DAY CAMPS

As communities consider a gradual scale up of activities towards pre-COVID-19 operating practices in centers for learning, such as K-12 schools and summer day camps, CDC offers the following recommendations to keep communities safe while resuming peer-to-peer learning and providing crucial support for parents and guardians returning to work. These recommendations depend on community monitoring to prevent COVID-19 from spreading. Communities with low levels of COVID-19 spread and those with confidence that the incidence of infection is genuinely low (e.g., communities that remain in low transmission or that have entered Step 2 or 3) may put in place the practices described below as part of a gradual scale up of operations. All decisions about following these recommendations should be made in collaboration with local health officials and other State and local authorities who can help assess the current level of mitigation needed based on levels of COVID-19 community transmission and the capacities of the local public health and healthcare systems, among other relevant factors. CDC is releasing this interim guidance, laid out in a series of three steps, to inform a gradual scale up of operations. The scope and nature of community mitigation suggested decreases from Step 1 to Step 3. Some amount of community mitigation is necessary across all steps until a vaccine or therapeutic drug becomes widely available.

Scaling Up Operations

- **In all Steps:**
  - Establish and maintain communication with local and State authorities to determine current mitigation levels in your community.
  - Protect and support staff and students who are at higher risk for severe illness, such as providing options for telework and virtual learning.
  - Follow CDC’s Guidance for Schools and Childcare Programs.
  - Provide teachers and staff from higher transmission areas (earlier Step areas) telework and other options as feasible to eliminate travel to schools and camps in lower transmission (later Step) areas and vice versa.
  - Encourage any other external community organizations that use the facilities also follow this guidance.

- **Step 1:** Schools that are currently closed, remain closed. E-learning or distance learning opportunities should be provided for all students. Support provision of student services such as school meal programs, as feasible. Camps should be restricted to children of essential workers and for children who live in the local geographic area only.

- **Step 2:** Remain open with enhanced social distancing measures and for children who live in the local geographic area only.

- **Step 3:** Remain open with distancing measures. Restrict attendance to those from limited transmission areas (other Step 3 areas) only.

Safety Actions

Promote healthy hygiene practices (Steps 1-3)

- Teach and reinforce washing hands and covering coughs and sneezes among children and staff.
- Teach and reinforce use of face coverings among all staff. Face coverings may be challenging for students (especially younger students) to wear in all-day settings such as school. Face coverings should be worn by staff and encouraged in students (particularly older students) if feasible and are most
essential in times when physical distancing is difficult. Information should be provided to staff and students on proper use, removal, and washing of cloth face coverings. Face coverings are not recommended for babies or children under the age of 2, or for anyone who has trouble breathing, or is unconscious, incapacitated or otherwise unable to remove the covering without assistance. Cloth face coverings are meant to protect other people in case the wearer is unknowingly infected (many people carry COVID-19 but do not have symptoms). Cloth face coverings are not surgical masks, respirators, or personal protective equipment.

- Have adequate supplies to support healthy hygiene behaviors, including soap, hand sanitizer with at least 60 percent alcohol (for staff and older children who can safely use hand sanitizer), paper towels, tissues, and no-touch trash cans.
- Post signs on how to stop the spread of COVID-19, properly wash hands, promote everyday protective measures, and properly wear a face covering.

Intensify cleaning, disinfection, and ventilation (Steps 1-3)

- **Clean and disinfect** frequently touched surfaces within the school and on school buses at least daily (for example, playground equipment, door handles, sink handles, drinking fountains) as well as shared objects (for example, toys, games, art supplies) between uses.
- To clean and disinfect school buses, see guidance for bus transit operators.
- Ensure safe and correct application of disinfectants and keep products away from children.
- Ensure ventilation systems operate properly and increase circulation of outdoor air as much as possible such as by opening windows and doors. Do not open windows and doors if they pose a safety or health risk (e.g., allowing pollens in or exacerbating asthma symptoms) risk to children using the facility.
- **Take steps** to ensure that all water systems and features (for example, drinking fountains, decorative fountains) are safe to use after a prolonged facility shutdown to minimize the risk of Legionnaires’ disease and other diseases associated with water.

Promote social distancing

- **Step 1 and 2**
  - Ensure that student and staff groupings are as static as possible by having the same group of children stay with the same staff (all day for young children, and as much as possible for older children).
  - Restrict mixing between groups.
  - Cancel all field trips, inter-group events, and extracurricular activities (Step 1).
  - Limit gatherings, events, and extracurricular activities to those that can maintain social distancing, support proper hand hygiene, and restrict attendance of those from higher transmission areas (Step 2; Note: restricting attendance from those in Step 1 areas).
  - Restrict nonessential visitors, volunteers, and activities involving other groups at the same time.
  - Space seating/desks to at least six feet apart.
  - Turn desks to face in the same direction (rather than facing each other), or have students sit on only one side of tables, spaced apart.
  - Close communal use spaces such as dining halls and playgrounds if possible; otherwise stagger use and disinfect in between use.
- If a cafeteria or group dining room is typically used, serve meals in classrooms instead. Serve individually plated meals and hold activities in separate classrooms and ensure the safety of children with food allergies.
- Stagger arrival and drop-off times or locations, or put in place other protocols to limit close contact with parents or caregivers as much as possible.
- Create social distance between children on school buses (for example, seating children one child per seat, every other row) where possible.

**Step 3**
- Consider keeping classes together to include the same group of children each day, and consider keeping the same child care providers with the same group each day.
- Allow minimal mixing between groups. Limit gatherings, events, and extracurricular activities to those that can maintain social distancing, support proper hand hygiene, and restrict attendance of those from higher transmission areas (Step 1 or 2 areas).
- Continue to space out seating and bedding (head-to-toe positioning) to six feet apart, if possible.
- Consider keeping communal use spaces closed, such as game rooms or dining halls, if possible; if this is not possible, stagger use and disinfect in between uses.
- Consider continuing to plate each child’s meal, to limit the use of shared serving utensils and ensure the safety of children with food allergies.
- Consider limiting nonessential visitors, volunteers, and activities involving other groups. Restrict attendance of those from higher transmission areas (Step 1 or 2 areas).
- Consider staggering arrival and drop-off times or locations, or put in place other protocols to limit close contact with parents or caregivers as much as possible.

**Limit sharing (Steps 1-3)**
- Keep each child’s belongings separated from others’ and in individually labeled containers, cubbies, or areas and taken home each day and cleaned, if possible.
- Ensure adequate supplies to minimize sharing of high touch materials to the extent possible (art supplies, equipment etc. assigned to a single student/camper) or limit use of supplies and equipment by one group of children at a time and clean and disinfect between use.
- If food is offered at any event, have pre-packaged boxes or bags for each attendee instead of a buffet or family-style meal. Avoid sharing of foods and utensils.
- Avoid sharing electronic devices, toys, books, and other games or learning aids.

**Train all staff (Steps 1-3)**
- Train all teachers and staff in the above safety actions. Consider conducting the training virtually, or, if in-person, ensure that social distancing is maintained.

**Check for signs and symptoms (Steps 1-3)**
- If feasible, conduct daily health checks (e.g. temperature screening and/or symptoms checking) of staff and students safely, respectfully, as well as in accordance with any applicable privacy laws or regulations. Confidentiality should be maintained.
School and camp administrators may use examples of screening methods in CDC’s supplemental Guidance for Child Care Programs that Remain Open as a guide for screening children and CDC’s General Business FAQs for screening staff.

Encourage staff to stay home if they are sick and encourage parents to keep sick children home.

Plan for when a staff member, child, or visitor becomes sick (Steps 1-3)

- Work with school administrators, nurses, and other healthcare providers to identify an isolation room or area to separate anyone who exhibits COVID-like symptoms. School nurses and other healthcare providers should use Standard and Transmission-Based Precautions when caring for sick people. See: What Healthcare Personnel Should Know About Caring for Patients with Confirmed or Possible COVID-19 Infection.
- Establish procedures for safely transporting anyone sick home or to a healthcare facility.
- Notify local health officials, staff, and families immediately of a possible case while maintaining confidentiality consistent with the Americans with Disabilities Act (ADA) and other applicable federal and state privacy laws.
- Close off areas used by a sick person and do not use before cleaning and disinfection. Wait 24 hours before you clean and disinfect. If it is not possible to wait 24 hours is, wait as long as possible. Ensure safe and correct application of disinfectants and keep disinfectant products away from children.
- Advise sick staff members and children not to return until they have met CDC criteria to discontinue home isolation.
- Inform those who have had close contact to a person diagnosed with COVID-19 to stay home and self-monitor for symptoms and to follow CDC guidance if symptoms develop. If a person does not have symptoms follow appropriate CDC guidance for home isolation.

Maintain healthy operations (Steps 1-3)

- Implement flexible sick leave policies and practices, if feasible.
- Monitor staff absenteeism and have a roster of trained back-up staff.
- Monitor health clinic traffic. School nurses and other healthcare providers play an important role in monitoring health clinic traffic and the types of illnesses and symptoms among students.
- Designate a staff person to be responsible for responding to COVID-19 concerns. Employees should know who this person is and how to contact them.
- Create a communication system for staff and families for self-reporting of symptoms and notification of exposures and closures.
- Support coping and resilience among employees and children.

Closing
Steps 1-3

- Check State and local health department notices daily about transmission in the area and adjust operations accordingly.
- In the event a person diagnosed with COVID-19 is determined to have been in the building and poses a risk to the community, programs may consider closing for a short time (1-2 days) for cleaning and disinfection.
INTERIM GUIDANCE FOR EMPLOYERS WITH WORKERS AT HIGH RISK

As workplaces consider a gradual scale up of activities towards pre-COVID-19 operating practices, it is particularly important to keep in mind that some workers are at higher risk for severe illness from COVID-19. These workers include individuals over age 65 and those with underlying medical conditions. Such underlying conditions include, but are not limited to, chronic lung disease, moderate to severe asthma, hypertension, severe heart conditions, weakened immunity, severe obesity, diabetes, liver disease, and chronic kidney disease that requires dialysis. Workers at higher risk for severe illness should be encouraged to self-identify, and employers should avoid making unnecessary medical inquiries. Employers should take particular care to reduce workers’ risk of exposure to COVID-19, while making sure to be compliant with relevant Americans with Disabilities Act (ADA) and Age Discrimination in Employment Act (ADEA) regulations. First and foremost, this means following CDC and the Occupational Safety and Health Administration (OSHA) guidance for reducing workplace exposure for all employees. All decisions about following these recommendations should be made in collaboration with local health officials and other State and local authorities who can help assess the current level of mitigation needed based on levels of COVID-19 community transmission and the capacities of the local public health and healthcare systems. In addition, the guidance offered below applies to workplaces generally; specific industries may require more stringent safety precautions. Finally, there may be essential workplaces in which the recommended mitigation strategies are not feasible. CDC is releasing this interim guidance, laid out in a series of three steps, to inform a gradual scale up of operations. The scope and nature of community mitigation suggested decreases from Step 1 to Step 3. Some amount of community mitigation is necessary across all steps until a vaccine or therapeutic drug becomes widely available.

Scaling Up Operations

• In all Steps:
  o Establish and maintain communication with local and State authorities to determine current mitigation levels in your community.
  o Protect employees at higher risk for severe illness by supporting and encouraging options to telework.
  o Consider offering workers at higher risk duties that minimize their contact with customers and other employees (e.g., restocking shelves rather than working as a cashier), if agreed to by the worker.
  o Encourage any other entities sharing the same work space also follow this guidance.
  o Provide employees from higher transmission areas (earlier Step areas) telework and other options as feasible to eliminate travel to workplaces in lower transmission (later Step) areas and vice versa.

• Step 1: Scale up only if business can ensure strict social distancing, proper cleaning and disinfecting requirements, and protection of their workers and customers; workers at higher risk for severe illness are recommended to shelter in place.

• Step 2: Scale up only if business can ensure moderate social distancing, proper cleaning and disinfecting requirements, and protection of their workers and customers; workers at higher risk for severe illness are recommended to shelter in place.

• Step 3: Scale up only if business can ensure limited social distancing, proper cleaning and disinfecting requirements, and protection of their workers and customers.
Safety Action

Promote **healthy hygiene practices** (Steps 1-3)

- Enforce *hand washing*, covering coughs and sneezes, and using *cloth face coverings* when around others where feasible;
- however, certain industries may require face shields.
- Ensure that adequate supplies to support healthy hygiene behaviors, including soap, hand sanitizer with at least 60 percent alcohol, tissues, paper towels, and no-touch trash cans.
- Post signs on how to stop the spread of COVID-19 properly wash hands, promote everyday protective measures, and properly wear a face covering.

Intensify cleaning, disinfection, and ventilation (Steps 1-3)

- **Clean and disinfect** frequently touched surfaces at least daily and shared objects between use.
- Avoid use or sharing of items that are not easily cleaned, sanitized, or disinfected.
- Ensure safe and correct application of disinfectants.
- Ensure that ventilation systems operate properly and increase circulation of outdoor air as much as possible such as by opening windows and doors. Do not open windows and doors if doing so poses a safety risk to individuals and employees using the workspace.
- Take steps to ensure that all water systems and features (for example, drinking fountains, decorative fountains) are safe to use after a prolonged facility shutdown to minimize the risk of Legionnaires’ disease and other diseases associated with water.

Promote social distancing (Steps 1-3)

- Limit service to drive-throughs, curbside take out, or delivery options, if possible (Step 1).
- Consider installing physical barriers, such as sneeze guards and partitions, and changing workspace layouts to ensure all individuals remain at least six feet apart.
- Close communal spaces, such as break rooms, if possible (Step 1) or stagger use and clean and disinfect in between uses (Steps 2 & 3).
- Encourage telework for as many employees as possible.
- Consider rotating or staggering shifts to limit the number of employees in the workplace at the same time.
- Replace in-person meetings with video- or tele-conference calls whenever possible.
- Cancel all group events, gatherings, or meetings of more than 10 people (Step 1), of more than 50 people (Step 2), and any events where social distancing of at least 6 feet cannot be maintained between participants (all Steps).
- Restrict (Step 1) or consider limiting (Step 2) any nonessential visitors, volunteers, and activities involving external groups or organizations.
- Limit any sharing of foods, tools, equipment, or supplies.

Limit travel and modify commuting practices (Steps 1-3)

- Cancel all non-essential travel (Step 1) and consider resuming non-essential travel in accordance with state and local regulations and guidance (Steps 2 & 3).
• Ask employees who use public transportation to consider using teleworking to promote social distancing.
• Train all managers and staff in the above safety actions. Consider conducting the training virtually, or if in-person, ensure that social distancing is maintained.

Monitoring and Preparing
Checking for signs and symptoms (Steps 1-3)

• Consider conducting routine, daily health checks (e.g., temperature and symptom screening) of all employees.
• If implementing health checks, conduct them safely and respectfully, and in accordance with any applicable privacy laws and regulations. Confidentiality should be respected. Employers may use examples of screening methods in CDC’s General Business FAQs as a guide.
• Encourage employees who are sick to stay at home.

Plan for when an employee becomes sick (Steps 1-3)

• Employees with symptoms (fever, cough, or shortness of breath) at work should immediately be separated and sent home.
• Establish procedures for safely transporting anyone sick to their home or to a healthcare facility.
• Notify local health officials, staff, and customers (if possible) immediately of a possible case while maintaining confidentiality consistent with the Americans with Disabilities Act (ADA) and other applicable federal and state privacy laws.
• Close off areas used by the sick person until after cleaning and disinfection. Wait 24 hours to clean and disinfect. If it is not possible to wait 24 hours, wait as long as possible before cleaning and disinfecting. Ensure safe and correct application of disinfectants and keep disinfectant products away from children.
• Inform those who have had close contact to a person diagnosed with COVID-19 to stay home and self-monitor for symptoms, and to follow CDC guidance if symptoms develop. If a person does not have symptoms, follow appropriate CDC guidance for home isolation.
• Sick employees should not return to work until they have met CDC’s criteria to discontinue home isolation.

Maintain healthy operations (Steps 1-3)

• Implement flexible sick leave and other flexible policies and practices, such as telework, if feasible.
• Monitor absenteeism of employees and create a roster of trained back-up staff.
• Designate a staff person to be responsible for responding to COVID-19 concerns. Employees should know who this person is and how to contact them.
• Create and test communication systems for employees for self-reporting and notification of exposures and closures.
• Support coping and resilience among employees.
Closing
Steps 1-3

- Check State and local health department notices daily about transmission in the area and adjust operations accordingly.
- Be prepared to consider closing for a few days if there is a case of COVID-19 in the workplace or for longer if cases increase in the local area.
INTERIM GUIDANCE FOR RESTAURANTS AND BARS

This guidance provides considerations for businesses in the food service industry (e.g., restaurants and bars) on ways to maintain healthy business operations and a safe and healthy work environment for employees, while reducing the risk of COVID-19 spread for both employees and customers. Employers should follow applicable Occupational Safety and Health Administration (OSHA) and CDC guidance for businesses to plan and respond to COVID-19. All decisions about implementing these recommendations should be made in collaboration with local health officials and other State and local authorities who can help assess the current level of mitigation needed based on levels of COVID-19 community transmission and the capacities of the local public health and healthcare systems. CDC is releasing this interim guidance, laid out in a series of three steps, to inform a gradual scale up of activities towards pre-COVID-19 operating practices. The scope and nature of community mitigation suggested decreases from Step 1 to Step 3. Some amount of community mitigation is necessary across all steps until a vaccine or therapeutic drug becomes widely available.

Scaling Up Operations

- In all Steps:
  - Establish and maintain communication with local and State authorities to determine current mitigation levels in your community.
  - Consider assigning workers at high risk for severe illness duties that minimize their contact with customers and other employees (e.g., managing inventory rather than working as a cashier, managing administrative needs through telework).
  - Provide employees from higher transmission areas (earlier Step areas) telework and other options as feasible to eliminate travel to workplaces in lower transmission (later Step) areas and vice versa.

- Step 1: Bars remain closed and restaurant service should remain limited to drive-through, curbside take out, or delivery with strict social distancing.
- Step 2: Bars may open with limited capacity; restaurants may open dining rooms with limited seating capacity that allows for social distancing.
- Step 3: Bars may open with increased standing room occupancy that allows for social distancing; restaurants may operate while maintaining social distancing.

Safety Actions

Promote healthy hygiene practices (Steps 1-3)

- Enforce hand washing, covering coughs and sneezes, and use of a cloth face coverings by employees when near other employees and customers.
- Ensure adequate supplies to support healthy hygiene practices for both employees and customers including soap, hand sanitizer with at least 60 percent alcohol (on every table, if supplies allow), paper towels, and tissues.
- Post signs on how to stop the spread of COVID-19 properly wash hands, promote everyday protective measures, and properly wear a face covering.

Intensify cleaning, disinfection, and ventilation (Steps 1-3)

- Clean and disinfect frequently touched surfaces (for example, door handles, work stations, cash registers) at least daily and shared objects (for example, payment terminals, tables, countertops/bars,
receipt trays, condiment holders) between use. Use products that meet EPA’s criteria for use against SARS-CoV-2 and that are appropriate for the surface. Prior to wiping the surface, allow the disinfectant to sit for the necessary contact time recommended by the manufacturer. Train staff on proper cleaning procedures to ensure safe and correct application of disinfectants.

- Make available individual disinfectant wipes in bathrooms.
- Wash, rinse, and sanitize food contact surfaces, food preparation surfaces, and beverage equipment after use.
- Avoid using or sharing items such as menus, condiments, and any other food. Instead, use disposable or digital menus, single serving condiments, and no-touch trash cans and doors.
- Use touchless payment options as much as possible, when available. Ask customers and employees to exchange cash or card payments by placing on a receipt tray or on the counter rather than by hand. Clean and disinfect any pens, counters, or hard surfaces between use or customer.
- Use disposable food service items (utensils, dishes). If disposable items are not feasible, ensure that all non-disposable food service items are handled with gloves and washed with dish soap and hot water or in a dishwasher. Employees should wash their hands after removing their gloves or after directly handling used food service items.
- Use gloves when removing garbage bags or handling and disposing of trash and wash hands afterwards.
- Avoid using food and beverage containers or utensils brought in by customers.
- Ensure that ventilation systems operate properly and increase circulation of outdoor air as much as possible such as by opening windows and doors. Do not open windows and doors if doing so poses a safety risk to employees, children, or customers.
- Take steps to ensure that all water systems and features (for example, drinking fountains, decorative fountains) are safe to use after a prolonged facility shutdown to minimize the risk of Legionnaires’ disease and other diseases associated with water.

Promote social distancing

**Step 1**

- Limit service to drive-through, delivery, or curb-side pick-up options only.
- Provide physical guides, such as tape on floors or sidewalks to ensure that customers remain at least six feet apart in lines or ask customers to wait in their cars or away from the establishment while waiting to pick up food. Post signs to inform customers of food pickup protocols.
- Consider installing physical barriers, such as sneeze guards and partitions at cash registers, or other food pickup areas where maintaining physical distance of six feet is difficult.
- Restrict the number of employees in shared spaces, including kitchens, break rooms, and offices to maintain at least a six-foot distance between people.
- Rotate or stagger shifts to limit the number of employees in the workplace at the same time.

**Step 2**

- Provide drive-through, delivery, or curb-side pick-up options and prioritize outdoor seating as much as possible.
- Reduce occupancy and limit the size of parties dining in together to sizes that ensure that all customer parties remain at least six feet apart (e.g., all tables and bar stools six feet apart, marking tables/stools that are not for use) in order to protect staff and other guests.
• Provide physical guides, such as tape on floors or sidewalks and signage on walls to ensure that customers remain at least six feet apart in lines or waiting for seating.
• Ask customers to wait in their cars or away from the establishment while waiting to be seated. If possible, use phone app technology to alert patrons when their table is ready to avoid touching and use of “buzzers.”
• Consider options for dine-in customers to order ahead of time to limit the amount of time spent in the establishment.
• Avoid offering any self-serve food or drink options, such as buffets, salad bars, and drink stations.
• Install physical barriers, such as sneeze guards and partitions at cash registers, bars, host stands, and other areas where maintaining physical distance of six feet is difficult.
• Limit the number of employees in shared spaces, including kitchens, break rooms, and offices to maintain at least a six-foot distance between people.

Step 3

• Provide drive-through, delivery, or curbside pick-up options and prioritize outdoor seating as much as possible.
• Consider reducing occupancy and limiting the size of parties dining in together to sizes that ensure that all customer parties remain at least six feet apart (e.g., all tables and bar stools six feet apart, marking tables/stools that are not for use) in order to protect staff and other guests.
• Provide physical guides, such as tape on floors or sidewalks and signage on walls, to ensure that customers remain at least six feet apart in lines or waiting for seating.
• If possible, use phone app technology to alert patrons when their table is ready to avoid touching and use of “buzzers.”
• Consider options for dine-in customers to order ahead of time to limit the amount of time spent in the establishment.
• Avoid offering any self-serve food or drink options, such as buffets, salad bars, and drink stations.
• Install physical barriers, such as sneeze guards and partitions at cash registers, bars, host stands, and other areas where maintaining physical distance of six feet is difficult.

Train all staff (Steps 1-3)

• Train all employees in the above safety actions while maintaining social distancing and use of face coverings during training.

Monitoring and Preparing

Checking for signs and symptoms (Steps 1-3)

• Consider conducting daily health checks (e.g., temperature and symptom screening) of employees.
• If implementing health checks, conduct them safely and respectfully, and in accordance with any applicable privacy laws and regulations. Confidentiality should be respected. Employers may use examples of screening methods in CDC’s General Business FAQs as a guide.
• Encourage staff who are sick to stay at home.
Plan for when an employee becomes sick (Steps 1-3)

- Employees with symptoms of COVID-19 (fever, cough, or shortness of breath) at work should immediately be sent to their home.
- Inform those who have had close contact to a person diagnosed with COVID-19 to stay home and self-monitor for symptoms, and to follow CDC guidance if symptoms develop. If a person does not have symptoms follow appropriate CDC guidance for home isolation.
- Establish procedures for safely transporting anyone sick to their home or to a healthcare facility.
- Notify local health officials, staff, and customers (if possible) immediately of any possible case of COVID-19 while maintaining confidentiality consistent with the Americans with Disabilities Act (ADA) and other applicable federal and state privacy laws.
- Close off areas used by a sick person and do not sure them until after cleaning and disinfection. Wait 24 hours before cleaning and disinfecting. If it is not possible to wait 24 hours, wait as long as possible. Ensure safe and correct application of disinfectants and keep disinfectant products away from children.
- Advise sick staff members not to return until they have met CDC’s criteria to discontinue home isolation.

Maintain healthy operations (Steps 1-3)

- Implement flexible sick leave and other flexible policies and practices, such as telework, if feasible.
- Monitor absenteeism of employees and create a roster of trained back-up staff.
- Designate a staff person to be responsible for responding to COVID-19 concerns. Employees should know who this person is and how to contact them.
- Create and test communication systems for employees for self-reporting and notification of exposures and closures.
- Support coping and resilience among employees.

Closing

Steps 1-3

- Check State and local health department notices about transmission in the area daily and adjust operations accordingly.
- Be prepared to consider closing for a few days if there is a case of COVID-19 in the establishment and for longer if cases increase in the local area.
INTERIM GUIDANCE FOR MASS TRANSIT ADMINISTRATORS

Mass transit is critical for many Americans to commute to and from work and to access essential goods and services. This guidance provides considerations for mass transit administrators to maintain healthy business operations and a safe and healthy work environment for employees, while reducing the risk of COVID-19 spread for both employees and passengers. Administrators should follow applicable guidance from the CDC and Occupational Safety and Health Administration (OSHA) for reducing workplace exposure. All decisions about following these recommendations should be made in collaboration with local health officials and other State and local authorities who can help assess the current level of mitigation needed based on levels of COVID-19 community transmission and the capacities of the local public health and healthcare systems. CDC is releasing this interim guidance, laid out in a series of three steps, to inform a gradual scale up of activities towards pre-COVID-19 operating practices. The scope and nature of community mitigation suggested decreases from Step 1 to Step 3. Some amount of community mitigation is necessary across all steps until a vaccine or therapeutic drug becomes widely available.

Resuming Full Service

- **In all Steps:**
  - Adjust routes between areas experiencing different levels of transmission (between areas in different Steps), to the extent possible.
  - Provide employees from higher transmission areas (earlier Step areas) telework and other options as feasible to eliminate travel to workplaces in lower transmission (later Step) areas and vice versa.
  - Establish and maintain communication with State and local health officials to determine current mitigation levels in the communities served. Decisions about how and when to resume full service should be based on these levels.
  - Follow CDC’s guidance on what bus transit operators, rail transit operators, transit maintenance workers, and transit station workers need to know about COVID-19.
  - Consider assigning workers at high risk of severe illness duties that minimize their contact with passengers and other employees.
  - Conduct worksite hazard assessments to identify COVID-19 prevention strategies, such as appropriate use of cloth face coverings or personal protective equipment (PPE), and follow the prevention strategies.

- **Step 1:** Restrict ridership to essential critical infrastructure workers in areas needing significant mitigation and maintain strict social distancing as much as possible.
- **Step 2:** Maintain social distancing between transit riders and employees as much as possible.
- **Step 3:** Encourage social distancing as much as possible.
Safety Actions

Promote healthy hygiene practices (Steps 1-3)

- Enforce everyday preventive actions such as hand washing, covering coughs and sneezes, and use of a cloth face covering by employees when around others, as safety permits. Provide employees with appropriate personal protective equipment as necessary and as available. Communicate with the public about the importance of hygiene, covering coughs and sneezes, and using cloth face coverings while using mass transportations, including posting signs in transit stations and vehicles on how to stop the spread of COVID-19, properly wash hands, promote everyday protective measures, and properly wear a face covering.

- Ensure adequate supplies to support healthy hygiene behaviors for transit operators, employees, and passengers in stations, including soap, hand sanitizer with at least 60 percent alcohol, paper towels, tissues, and no-touch trash cans.

- Post signs on how to stop the spread of COVID-19 properly wash hands, promote everyday protective measures, and properly wear a face covering.

Intensify cleaning, disinfection, and ventilation (Steps 1-3)

- Clean and disinfect frequently touched surfaces (for example, kiosks, digital interfaces such as touchscreens and fingerprint scanners, ticket machines, turnstiles, handrails, restroom surfaces, elevator buttons) at least daily or between use as feasible.

- Clean and disinfect the operator area between operator shifts.

- Use touchless payment and no-touch trash cans and doors as much as possible, when available. Ask customers and employees to exchange cash or credit cards by placing in a receipt tray or on the counter rather than by hand and wipe any pens, counters, or hard surfaces between each use or customer.

- Avoid using or sharing items that are not easily cleaned, sanitized, or disinfected, such as disposable transit maps.

- Ensure safe and correct application of disinfectants.

- Use gloves when removing garbage bags or handling and disposing of trash and wash hands afterwards.

- Ensure that ventilation systems operate properly and increase circulation of outdoor air as much as possible such as by opening windows and doors. Do not open windows and doors if they pose a safety risk to passengers or employees, or other vulnerable individuals.

- Take steps to ensure that all water systems and features (for example, drinking fountains, decorative fountains) are safe to use after a prolonged facility shutdown to minimize the risk of Legionnaires’ disease and other diseases associated with water.

Promote social distancing

Step 1 and Step 2

- Institute measures to physically separate or create distance of at least six feet between all occupants to the extent possible. This may include:
  - Asking bus passengers to enter and exit the bus through rear doors, while allowing exceptions for persons with disabilities.
• Closing every other row of seats.
• Reducing maximum occupancy of buses and individual subway and train cars and increasing service on crowded routes as appropriate.

• Provide physical guides to ensure that customers remain at least six feet apart while on vehicles and at transit stations and stops. For example, floor decals, colored tape, or signs to indicate where passengers should not sit or stand can be used to guide passengers.
• Install physical barriers, such as sneeze guards and partitions at staffed kiosks and on transit vehicles to the extent practicable.
• Close communal spaces, such as break rooms, if possible; otherwise, stagger use and clean and disinfect in between uses.

Step 3

• Consider or continue instituting measures to physically separate or create distance between occupants.
• Provide physical guides to help customers maintain physical distance while on vehicles and at transit stations and stops. For example, floor decals, colored tape, or signs to indicate where passengers should not sit or stand can be used to guide passengers.
• Install or maintain physical barriers, such as sneeze guards and partitions at staffed kiosks and on transit vehicles to the extent practicable.

Train employees (Steps 1-3)

• Train all employees in the above safety actions while maintaining social distancing during training.

Monitoring and Preparing
Checking for signs and symptoms (Steps 1-3)

• Consider conducting daily health checks (e.g., temperature screening and/or symptom checking) of all employees.
• If implementing health checks, conduct them safely and respectfully, and in accordance with any applicable privacy laws and regulations. Confidentiality should be respected. Employers may use examples of screening methods in CDC’s General Business FAQs as a guide.
• Encourage staff who are sick to stay at home.

Plan for when an employee becomes sick (Steps 1-3)

• Employees with symptoms of COVID-19 (fever, cough, or shortness of breath) at work should immediately be sent home.
• Inform those who have had close contact to a person diagnosed with COVID-19 to stay home and self-monitor for symptoms, and to follow CDC guidance if symptoms develop. If a person does not have symptoms follow appropriate CDC guidance for home isolation.
• Establish procedures for safely transporting anyone sick to their home or to a healthcare facility.
• Notify local health officials, staff, and customers (if possible) immediately of any possible case of COVID-19 while maintaining confidentiality consistent with the Americans with Disabilities Act (ADA) and other applicable federal and state privacy laws.
• Close off areas used by a sick person and do not use until after cleaning and disinfection. Wait 24 hours before cleaning and disinfecting. If 24 hours is not feasible, wait as long as possible. Ensure safe and correct application of disinfectants and keep disinfectant products away from children. Affected vehicles can be used immediately after cleaning and disinfection.

• Advise sick staff members not to return until they have met CDC’s criteria to discontinue home isolation.

• Implement safety practices for critical infrastructure workers who may have had exposure to a person with suspected or confirmed COVID-19.

Maintain healthy operations (Steps 1-3)

• Implement flexible sick leave and other flexible policies and practices, if feasible.

• Monitor absenteeism of employees and create a roster of trained back-up staff.

• Designate a staff person to be responsible for responding to COVID-19 concerns. Employees and customers should know who this person is and how to contact them.

• Create and test communication systems for employees and customers for self-reporting of symptoms and notification of exposures and closures.

• Support coping and resilience among employees.

Adjusting Service

Steps 1-3

• Coordinate with State and local health department officials about transmission in the area as frequently as possible and adjust operations accordingly.

• Be prepared to consider adjusting services as appropriate if the community mitigation level increases in the local area.

• Continue communication with staff and the public about decision-making.